Cardiomyocyte group, pharmaceutical composition, method for producing cardiomyocyte group, and myocardial sphere
A cardiomyocyte group and myocardial sphere derived from human pluripotent stem cells, with specific characteristics, address the limitations of current cardiac repair methods by ensuring safe, effective engraftment and reduced arrhythmia risk, enhancing myocardial regeneration and heart function.
Patent Information
- Application Number
- PCT/JP2024/019949
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current methods for using human pluripotent stem cell-derived cardiomyocytes in cardiac repair face challenges such as limited engraftment rate, electrical integration with host cardiomyocytes, and the risk of transplant-related arrhythmias, with existing solutions being clinically unacceptable due to safety concerns and complexity in manufacturing and quality control.
A cardiomyocyte group with at least 90% cardiac troponin T-positive cells, exhibiting spontaneous heartbeats of 0-60 times/min within 30 days, and a myocardial sphere formed by spheroidizing the cardiomyocyte group, which can be used in a pharmaceutical composition for treating heart failure, ensuring high purity, safe transplantation, and reduced arrhythmia incidence.
The cardiomyocyte group and myocardial sphere enable effective electrical integration, long-term engraftment, and reduced arrhythmia risk, making them suitable for clinical application by enhancing myocardial regeneration and improving heart function.
Smart Images

Figure 000060 
Figure 000061 
Figure 000062
Abstract
Description
Cardiomyocyte population, pharmaceutical composition, method for producing cardiomyocyte population, and cardiomyospheric
[0001] The present invention relates to a cardiomyocyte population, a pharmaceutical composition, a method for producing a cardiomyocyte population, and cardiomyospheric cells. This application claims priority based on Japanese Patent Application No. 2023-088954, filed on May 30, 2023, the contents of which are incorporated herein by reference.
[0002] When a heart attack results in the loss of a large number of cardiomyocytes, the myocardial tissue is eventually replaced by non-contractile fibrous tissue, resulting in lifelong heart failure. Clinical applications of human pluripotent stem cell-derived cardiomyocytes for cardiac repair are currently being investigated. Transplantation of human pluripotent stem cell-derived cardiomyocytes (hereinafter sometimes referred to as "hPSC-CM") into myocardial tissue is expected to regenerate myocardial tissue. Regenerative medicine using the above-mentioned hPSC-CM is considered promising because, theoretically, it is possible to produce large quantities of hPSC-CM in vitro.
[0003] Numerous studies, including those by the present inventors, have disclosed methods for producing large quantities of highly pure human pluripotent stem cell-derived cardiomyocytes (see Patent Documents 1 to 3). Proof-of-concept studies involving transplantation of these cardiomyocytes into animal models have been conducted, including a study in which cardiomyocytes differentiated from human ES cells using activin A and BMP4 were transplanted into rats with induced myocardial infarction (see Non-Patent Document 1), and a study in which cardiomyocytes differentiated from human iPS cells were transplanted into the infarcted hearts of immunodeficient mice (see Non-Patent Document 2). These studies have confirmed the engraftment of transplanted cardiomyocytes into the recipient heart over a certain period of time. Furthermore, several strategies have been tested to improve the engraftment rate of cardiomyocytes into recipient myocardial tissue, including co-transplantation with Matrigel (registered trademark) and genetic modification of PSC-CM to promote cell proliferation. While these techniques have been shown to be effective in improving the engraftment rate of cardiomyocytes, most of them are currently clinically unacceptable.
[0004] Furthermore, the mere engraftment of transplanted hPSC-CMs into a recipient heart is not sufficient for myocardial regenerative medicine purposes. Myocardial regenerative medicine requires electrical integration between transplanted cardiomyocytes and recipient cardiomyocytes in the damaged recipient heart. Electrical integration between recipient cardiomyocytes and transplanted cardiomyocytes in the damaged recipient heart has been confirmed in studies in which human ES cell-derived cardiomyocytes were transplanted into damaged guinea pig hearts (see, for example, Non-Patent Documents 3 and 4 and Patent Document 4). However, the findings obtained from these studies did not confirm whether clinical-scale cardiomyocyte transplantation can be performed safely and effectively to achieve myocardial regeneration in terms of engraftment, electrical integration, and therapeutic effects on the damaged heart in the recipient heart, given the lack of physiologically relevant animal models used in these studies.
[0005] Tests have also been conducted in animal models, such as primates and pigs, which are relatively suitable for extrapolation to humans. However, cardiomyocytes induced to differentiate from human pluripotent stem cells typically exhibit fetal or neonatal phenotypes. Therefore, significant differences in the electrical properties of human cardiac cardiomyocytes and those derived from pluripotent stem cells have been noted, due to factors such as maturity. New problems have been reported, such as limited engraftment rates of transplanted pluripotent stem cell-derived cardiomyocytes and the induction of transplant-associated arrhythmias in the recipient's heart (see, for example, Non-Patent Documents 5, 6, 7, and 8). While methods for suppressing transplant-associated arrhythmias, such as those using antiarrhythmic drugs to reduce arrhythmias (see, for example, Non-Patent Document 9), have been disclosed, these methods pose problems such as the burden on the recipient. Additionally, hPSC-CMs (see Non-Patent Document 10) have been reported in which genes such as ion channels have been deleted using genome editing technology; however, using gene-edited cells as transplant cells is not desirable for reasons such as the possibility that gene editing may cause changes in unintended locations, which could lead to undesirable mutations and unpredictable effects, and the complexity of the manufacturing and quality control processes.
[0006] International Publication No. WO 2007 / 088874 International Publication No. WO 2016 / 010165 International Publication No. WO 2018 / 074457 U.S. Patent Application Publication No. 2020 / 0407687
[0007] Laflamme MA. et al., Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. (2007) Na Biotechnol., 25, 1015-1024.Funakoshi S. et al., Enhanced engraftment, proliferation and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes . (2016) Sci Rep., 6, 19111.Shiba Y., et al., Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. (2012) Nature, 489, 322-5.Dhahri W. et al., In Vitro Matured Human Pluripotent Stem Cell-Derived Cardiomyocytes Form Grafts With Enhanced Structure and Function in Injured Hearts. (2022) Circulation, 145, 1412-1426.Liw YW. et al., Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. (2018) Nat Biotechnol., 36, 597-605.Chong JJ. et al., Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. (2014) Nature, 510, 273-7.Shiba Y. et al., Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. (2016) Nature, 538, 388-391.Romagnuolo R. et al., Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias. (2019) Stem Cell Reports., 12, 967-981.Nakamura K. et al., Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes. (2021) Stem Cell Reports., 16, 2473-2487.Marchiano S. et al.,Gene editing to prevent ventricular arththmias associated with cardiomyocyte cell therapy.(2023)Cell Stem Cell.,30, 396-414.
[0008] Previously reported human pluripotent stem cell-derived cardiomyocytes have not fully met all of the requirements for clinical application: (i) the ability to easily produce highly purified cardiomyocytes, (ii) the ability to safely transplant them into humans, (iii) the ability to electrically integrate with the recipient's cardiomyocytes and survive for a long time while maintaining maturity, thereby regenerating the damaged part of the recipient's heart, and (iv) the low incidence of severe ventricular arrhythmias lasting for a certain period of time in the recipient. Furthermore, the structural and functional characteristics required for human pluripotent stem cell-derived cardiomyocytes that satisfy the above requirements have not been elucidated, based on their mechanism of action, etc. Therefore, the only way to confirm or evaluate whether a human pluripotent stem cell-derived cardiomyocyte is able to satisfy the above requirements is to transplant the human pluripotent stem cell-derived cardiomyocytes obtained by various production methods into the myocardial tissue of a primate or other species similar to humans.
[0009] Therefore, an object of the present invention is to provide a cardiomyocyte population derived from human pluripotent stem cells, cardiomyocyte spheroids formed from the cardiomyocyte population, a pharmaceutical composition containing the cardiomyocyte population and / or the cardiomyocyte spheroids as active ingredients, a method for producing the cardiomyocyte population, and a method for producing the cardiomyocyte population, which can meet the conditions necessary for clinical application.
[0010] The present disclosure includes the following aspects. [1] A cardiomyocyte cell population comprising ventricular myocytes differentiated from human pluripotent stem cells, the cardiomyocyte cell population having the following characteristics (1), (2), and (3): (1) cardiac troponin T-positive cells account for 90% or more of all live cells, (2) a spontaneous beating rate of 0 to 60 beats / minute, and (3) differentiation has occurred within 30 days. [2] The cardiomyocyte cell population according to [1], having a spontaneous beating rate of 0 to 50 beats / minute. [3] A pharmaceutical composition comprising at least one selected from the group consisting of the cardiomyocyte cell population according to [1] or [2] and cardiomyocyte spheroids formed by spheroidizing the cardiomyocyte cell population, and a pharmaceutically acceptable carrier. [4] The pharmaceutical composition according to [3], wherein the proportion of live cells among all cells in the cardiomyocyte cell population is 80% or more. [5] The pharmaceutical composition according to [3], wherein the proportion of cells constituting cardiomyocytes among all cells contained in the pharmaceutical composition is 60% or more. [6] The pharmaceutical composition according to any one of [3] to [5], used for treating heart failure. [7] A method for producing a cardiomyocyte cell group according to [1] or [2], comprising: (a) a step of expanding human pluripotent stem cells; (b) a step of culturing the expanded human pluripotent stem cells under conditions for differentiating the expanded human pluripotent stem cells into cardiomyocytes, to produce a cell group containing 60% or more cardiomyocytes; and (c) a step of removing human pluripotent stem cells and non-cardiomyocytes from the cell group. [8] A cardiomyocyte spheroid obtained by forming the cardiomyocyte cell group according to [1] or [2] into a spheroid. [9] The cardiomyocyte spheroid according to [8], wherein the cardiomyocyte spheroid has a diameter of 50 to 300 μm.
[10] A method for producing cardiomyocyte spheroids, comprising: a step of suspending the cardiomyocyte cell group according to [1] or [2] in a medium, and then statically culturing the cardiomyocyte cell group in an incubator having microwells on the bottom.
[0011] According to the present invention, there are provided cardiomyocyte populations derived from human pluripotent stem cells, cardiomyocyte spheroids formed from the cardiomyocyte populations, pharmaceutical compositions containing the cardiomyocyte populations and / or the cardiomyocyte spheroids as active ingredients, methods for producing the cardiomyocyte populations, and methods for producing the cardiomyocyte spheroids, which can meet the conditions necessary for clinical application.
[0012] (b) shows the results of flow cytometry analysis of the cardiac troponin T positivity rate of the human iPS cell-derived cardiomyocyte cell group prepared in Example 1(1). (a) shows the results of flow cytometry analysis of the cardiac troponin T positivity rate of the cell group before purification. (b) shows the action potential pattern obtained by electrophysiological analysis using the patch clamp method for the human iPS cell-derived cardiomyocyte cell group prepared in Example 1(1). (c) shows the spontaneous beat rate (beat rate), maximum diastolic potential (MDP), and action potential duration at 90% repolarization (APD90) obtained by electrophysiological analysis using the patch clamp method for the human iPS cell-derived cardiomyocyte cell group prepared in Example 1(1). (d) shows the action potential waveforms obtained by analyzing the drug responsiveness of the human iPS cell-derived cardiomyocyte cell group prepared in Example 1(1) to isoproterenol, amiodarone, and ivabradine. The spontaneous beats per minute of the cardiomyocyte group derived from human iPS cells prepared in Example 1(1) were analyzed for drug responsiveness to isoproterenol, amiodarone, and ivabradine. The results of immunocytochemical analysis of the cardiomyocyte group derived from human iPS cells prepared in Example 1(1) are shown. The results of measuring the spontaneous beats of the cardiomyocyte group derived from human iPS cells prepared in Example 1(1) (purified hiPSC-CMs) and the cell group before purification (pre-purified hiPSC-CMs) are shown. The viability of cells contained in cardiomyocytes prepared in Example 2(1) is shown. In Example 3, the results of measuring the sarcomere length of host cardiomyocytes and transplanted cardiomyocytes in cynomolgus monkeys transplanted with cardiomyocytes prepared in Example 2(1) are shown. In Example 2(2), the results of immunohistochemical staining of the cardiomyocytes prepared in Example 2(1) after long-term culture are shown. Day 28: 28 days after the start of culture; Day 56: 56 days after the start of culture; Day 84: 84 days after the start of culture. A, D, G: Stained with CytoRed and DAPI; B, E, H: Stained with cardiac troponin T (cTnT) and DAPI; C, F, I: Stained with CytoRed, cTnT, and DAPI.In Example 2(2), dispersed cardiomyocyte groups derived from human iPS cells expressing modified luciferase (Dispersed hiPSC-CMs) and cardiomyocyte spheres expressing modified luciferase (hiPSC-CSs) were transplanted into adult male NOG mice, and the results of detecting bioluminescence signals in the transplanted mice are shown. Figure 2D is a graph of the bioluminescence signals detected. In Example 3, the cardiomyocyte spheres (2 x 10 cardiomyocytes) produced in Example 2(1) were transplanted into adult male NOG mice. 7 The graph shows the results of measuring the trough level of cyclosporine in the peripheral blood of cynomolgus monkeys transplanted with cardiomyocytes (equivalent to 6 x 10 cells). The shaded area indicates the trough level of cyclosporine required to suppress acute rejection in heart transplantation. In Example 3, the cardiomyocytes prepared in Example 2(1) (equivalent to 6 x 10 cells) were transplanted. 7 1 shows the results of measuring the trough levels of cyclosporine in the peripheral blood of cynomolgus monkeys transplanted with cardiomyosphers (equivalent to 1000 cells / ml). The shaded area indicates the trough level of cyclosporine for suppressing acute rejection in heart transplantation. In Example 3, the results of measuring the left ventricular fractional shortening (FS) by echocardiography before transplantation, 4 weeks after transplantation (4w after transplantation), and 12 weeks after transplantation (12w after transplantation) in cynomolgus monkeys transplanted with cardiomyosphers produced in Example 2(1) are shown ... before transplantation, 4 weeks after transplantation (4w after transplantation), and 12 weeks after transplantation (12w after transplantation) in cynomolgus monkeys transplanted with cardiomyosphers produced in Example 2(1) are shown. In Example 3, the results of measuring the left ventricular fractional shortening (FS) before transplantation, 4 weeks after transplantation (4w after transplantation), and 12 weeks after transplantation (12w after transplantation) in cynomolgus monkeys transplanted with cardiomyosphers produced in Example 2(1) are shown. In Example 3, the results of measuring the left ventricular fractional shortening (FS) before transplantation, 4 weeks after transplantation (4w after transplantation), and 12 weeks after transplantation (12w after transplantation) in cynomolgus monkeys transplanted with cardiomyosphers produced in Example 2(1) are shown. In Example 3 In Example 3, the results of histological examination of cynomolgus monkeys transplanted with cardiomyocytes produced in Example 2(1) are shown. In Example 3, echocardiograms are shown of cynomolgus monkeys transplanted with cardiomyocytes produced in Example 2(1) or a vehicle before transplantation, 4 weeks after transplantation (4w post-transplantation), and 12 weeks after transplantation (12w post-transplantation). The scale bar indicates 5 cm. In Example 3, the results of histological examination of cynomolgus monkeys transplanted with cardiomyocytes produced in Example 2(1) or a vehicle before transplantation, 4 weeks after transplantation (4w post-transplantation), and 12 weeks after transplantation (12w post-transplantation) are shown. The scale bar indicates 5 cm. In Example 3, the results of histological examination of cynomolgus monkeys transplanted with cardiomyocytes produced in Example 2(1) (6 x 10 71 shows the measured values of LVEF and FS before transplantation, 4 weeks after transplantation (4w post-transplantation), and 12 weeks after transplantation (12w post-transplantation) in cynomolgus monkeys transplanted with cardiomyocytes (equivalent to 100 cells / ml) or a vehicle. In Example 3, Holter electrocardiograms of cynomolgus monkeys transplanted with cardiomyocytes produced in Example 2(1) or a vehicle are shown. In Experimental Example 3, the results of measuring left ventricular shunt fraction (FS) by echocardiographic analysis are shown in cynomolgus monkeys transplanted with human iPS cell-derived cardiomyocytes or a vehicle are shown. hiPSC-CSs (purified): cardiomyocytes produced in Example 2(1); hiPSC-CSs (non-purified): cardiomyocytes produced from a group of human iPS cell-derived cardiomyocytes that had not been purified. In Example 3, cardiac troponin T (cTnT) and brain natriuretic peptide (BNP) were measured in the serum of cynomolgus monkeys transplanted with the cardiomyocytes prepared in Example 2(1) or a vehicle. A, B: 2 x 10 cardiomyocytes 7 C, D: 6 x 10 cardiomyocytes 7 1000 cells / ml. Example 3 shows the duration of arrhythmia in individuals that developed transient arrhythmia in cynomolgus monkeys transplanted with the cardiomyosphers produced in Example 2(1). *p<0.05 versus pre-Tx; #p<0.05 between vehicle and hiPSC-CSs. Example 3 shows the results of histological examination of the heart (A), lungs (B, F), liver (C, G), kidneys (D, H), and spleen (E, I) in cynomolgus monkeys transplanted with the cardiomyosphers produced in Example 2(1). The scale bars in A to D represent 1 cm. The scale bar in E represents 5 mm. The scale bar in I represents 200 μm.
[0013] A numerical range expressed using "to" means a range that includes the numerical values before and after "to" as the lower and upper limits.
[0014] The term "comprise" means that it may contain components other than the target component. The term "consist of" means that it does not contain components other than the target component. The term "consist essentially of" means that it does not contain components other than the target component in a manner that would exert a special function (such as a manner that would completely lose the effects of the invention). In this specification, when "comprise" is used, it includes both "consist of" and "consist essentially of" embodiments.
[0015] The proteins, peptides, polynucleotides (DNA, RNA), vectors, cells, cell populations, and cardiomyosphers described herein may be isolated. "Isolated" refers to a state in which the protein is in its natural state or is separated from other components. "Isolated" may be substantially free of other components. "Substantially free of other components" means that the content of other components contained in the isolated component is negligible. The content of other components contained in the isolated component may be, for example, 10% by mass or less, 5% by mass or less, 4% by mass or less, 3% by mass or less, 2% by mass or less, 1% by mass or less, 0.5% by mass or less, or 0.1% by mass or less. The proteins, peptides, polynucleotides (DNA, RNA), vectors, cells, cell populations, and cardiomyosphers described herein may be isolated proteins, isolated peptides, isolated polynucleotides (isolated DNA, isolated RNA), isolated vectors, isolated cells, isolated cell populations, and isolated cardiomyosphers, respectively.
[0016] As used herein, the ratio (proportion) of specific cells in a cell population refers to the ratio of the number of specific cells to the total number of cells in the cell population, and is calculated using the following formula: Ratio (%) of specific cells = Number of specific cells / Total number of cells in the cell population × 100
[0017] (Cardiomyocyte population) A first aspect of the present disclosure is a cardiomyocyte population comprising ventricular myocytes differentiated from human pluripotent stem cells. The cardiomyocyte population has the following characteristics (1), (2), and (3): (1) cardiac troponin T-positive cells account for 90% or more of all living cells; (2) spontaneous pulsation is 0 to 60 beats per minute; and (3) differentiation has been initiated within 30 days.
[0018] The cardiomyocyte population of this embodiment has the above characteristics (1), (2), and (3), and is therefore a cardiomyocyte population that can satisfy the following conditions (i) to (iv) required for clinical application: (i) A highly pure cardiomyocyte population that can be easily produced. (ii) Able to be safely transplanted into humans. (iii) Able to regenerate damaged parts of the recipient's heart by electrically integrating with the recipient's cardiomyocytes and remaining engrafted for a long time while maintaining maturity. (iv) A low incidence of severe ventricular arrhythmia that lasts for a certain period of time in the recipient.
[0019] The cardiomyocyte population of this embodiment preferably satisfies one or more of the above (i) to (iv), more preferably two or more, even more preferably three or more, and particularly preferably all four. By satisfying the above conditions (i) to (iv), the cardiomyocyte population of this embodiment can be said to be a cardiomyocyte population that can be used clinically.
[0020] <Human Pluripotent Stem Cells> "Pluripotent stem cells" are cells that have the ability to self-proliferate and pluripotency. Specific examples of pluripotent stem cells include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), embryonic germ cells (EG cells), and germline stem cells (GS cells), as well as cells with pluripotency induced from these pluripotent stem cells. "Pluripotent stem cells" are not particularly limited as long as they are cells with the ability to self-proliferate and pluripotency, and also include unknown cells with properties equivalent to those of the ES cells and iPS cells exemplified above.
[0021] Whether a cell is a pluripotent stem cell can be determined based on the presence or absence of properties specific to pluripotent stem cells, the expression of various markers specific to pluripotent stem cells, etc. For example, properties specific to pluripotent stem cells include the ability to self-renew and the ability to differentiate into different types of cells with properties different from those of pluripotent stem cells. Other properties specific to pluripotent stem cells include the ability to form teratomas and chimeric mice.
[0022] Various markers specific to pluripotent stem cells (hereinafter referred to as "pluripotent stem cell markers") are factors that are specifically expressed in pluripotent stem cells, and examples thereof include Oct3 / 4, Nanog, Sox2, SSEA-1, SSEA-3, SSEA-4, TRA1-60, TRA1-81, Lin28, Fbx15, SSEA-5, GDF3, KLF4, and CLDN6. When expression of at least one of these pluripotent stem cell markers is observed, the cells can be determined to be pluripotent stem cells. One type of pluripotent stem cell marker may be used alone, or two or more types may be used in combination. In one embodiment, cells that express Oct3 / 4 may be determined to be pluripotent stem cells. The expression of pluripotent stem cell markers in cells can be confirmed using known methods such as RT-PCR and microarrays.
[0023] Human pluripotent stem cells may be human ES cells, human iPS cells, human EG cells, or human GS cells, with human ES cells or human iPS cells being preferred, and human iPS cells being more preferred. "Human iPS cells" are pluripotent stem cells artificially generated from non-pluripotent cells, such as adult somatic cells, and methods for producing human iPS cells are well known in the art. Specifically, human iPS cells are produced by introducing one or more reprogramming factors into any somatic cell, such as a fibroblast, hematopoietic cell, or epidermal cell. Examples of reprogramming factors include Oct3 / 4, Sox2, c-Myc, l-Myc, Klf4, Nanog, and LIN28. Pluripotent stem cells can be confirmed and selected using indicators such as the expression of genes and / or proteins specific to the stem cells. Several types of human iPS cell lines are provided by the Kyoto University iPS Cell Research Foundation (53 Kawaramachi, Shogoin, Sakyo-ku, Kyoto City, Kyoto Prefecture, Japan). These human iPS cell lines may be used as human pluripotent stem cells. Specific examples of human iPS cell lines provided by the Kyoto University iPS Cell Research Foundation include the Ff-I01 strain, the Ff-I14 strain, the Ff-I01s01 strain, the Ff-I14s03 strain, the Ff-I14s04 strain, the QHJI-I14s04 strain, the Ff-MH09s01 strain, and the Ff-MH15s02 strain. Of these cells, the Ff-I14 strain, the Ff-I14s04 strain, and the QHJI-I14s04 strain are preferably used. All of the above iPS cells are HLA haplotype homozygous human iPS cells. For clinical applications, it is preferable to use clinical-grade cell lines. Human iPS cells may be provided by a cell bank such as the American Type Culture Collection (ATCC). Commercially available human iPS cells may also be used.
[0024] <Cardiomyocyte Population> The cardiomyocyte population of this embodiment includes cardiomyocytes differentiated from human pluripotent stem cells (hPSC-CM), particularly mature ventricular myocytes. Cardiomyocytes refer to cells positive for at least one of sarcomeric α-actinin, cardiac troponin T (cTnT), and troponin I type 1 (TNNI1). Ventricular myocytes refer to cells positive for cardiac troponin T and / or myosin light chain 2v (MLC2v). Cardiomyocytes are typically myocardial cells with spontaneous beating ability. Ventricular myocytes are a type of cardiomyocyte that can constitute ventricular muscle. "Cyclical progenitor cells" refer to precursor cells of the cardiomyocytes that are positive for at least one of Nkx2.5, GATA4, MEF2C, and MESP1. As used herein, the term "non-cardiomyocytes" refers to cells that do not fall into the category of either cardiac myocytes or cardiac progenitor cells, and specific examples of such cells include smooth muscle cells and endothelial cells.
[0025] The cardiomyocyte population of this embodiment satisfies all of the following conditions: (1) cardiac troponin T-positive cells account for 90% or more of all living cells; (2) spontaneous pulsation is 0 to 60 beats per minute; and (3) differentiation has commenced within 30 days.
[0026] A "cell population" refers to a cell population consisting of two or more cells of the same or different types. A "cardiomyocyte population" refers to a cell population containing cardiomyocytes, and may be composed only of cardiomyocytes, or may also contain cells other than cardiomyocytes (e.g., non-cardiomyocytes). At least a portion of the cardiomyocytes contained in the cardiomyocyte population of this embodiment are ventricular myocytes. The cardiomyocyte population may contain, in addition to ventricular myocytes, cardiomyocytes other than ventricular myocytes (e.g., cardiac progenitor cells, atrial myocytes, etc.). The cardiomyocyte population of the present invention can be produced from human pluripotent stem cells by the method described below.
[0027] <(1) Cardiac troponin T-positive cells account for 90% or more of all living cells> Cardiac muscle troponin T (cTnT) is a protein that constitutes myofibrils in cardiac muscle and is known as a cardiomyocyte marker. Cardiac troponin T-positive cells can be said to be cardiomyocytes. Human cardiac troponin T is a protein encoded by the TNNT2 gene (Gene ID: 7139). As used herein, "positive cells" means that the target protein or gene is expressed in an amount that can be detected by a method known in the art. Protein detection can be performed using immunological assays using antibodies, such as ELISA, immunostaining, and flow cytometry. In addition, in the case of proteins that are expressed intracellularly but not on the cell surface (e.g., transcription factors or their subunits), the target protein can be detected by expressing a reporter protein together with the protein and detecting the reporter protein. Gene detection can be performed using, for example, nucleic acid amplification methods and nucleic acid detection methods such as RT-PCR, microarrays, and RNAseq. Expression of a target protein or gene can be determined using common techniques. For example, when using flow cytometry, if the expression level of the target protein in the target cells is relatively high compared to the expression level in a control group in which the expression of the protein is negative, the target cells can be determined to be positive for the target protein. As used herein, "negative" means that the expression level of the target protein or gene is below the lower limit of detection by all or any of the known techniques described above. The lower limit of detection for the expression of the target protein or gene may vary depending on the technique, but can be determined using common techniques.
[0028] The proportion of cardiac troponin T-positive cells in the cardiomyocyte cell group is not particularly limited, as long as it is 90% or more of the total number of viable cells in the cardiomyocyte cell group. The proportion of cardiac troponin T-positive cells in the cardiomyocyte cell group is preferably 90% or more of the total number of viable cells in the cardiomyocyte cell group, more preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, and particularly preferably 99% or more or 99.5% or more. The proportion of cardiac troponin T-positive cells in all viable cells in the cardiomyocyte cell group may be 90 to 100%, 95 to 100%, 96 to 100%, 97 to 100%, 98 to 100%, 99 to 100%, or 99.5 to 100% of the total number of viable cells in the cardiomyocyte cell group. The proportion of cardiac troponin T-positive cells among all viable cells in a cardiomyocyte population can be determined by measuring the number of cardiac troponin T-positive cells using any of the above-mentioned methods, detecting the number of all viable cells using a commonly used method (e.g., flow cytometry gating, etc.), and calculating the ratio. The number of cardiac troponin T-positive cells can be preferably confirmed by flow cytometry analysis using an antibody against cardiac troponin T. Commercially available anti-cardiac troponin T antibodies can be used for flow cytometry analysis. For example, viable cells in a cardiomyocyte population can be selected by flow cytometry, etc., and the number of cardiac troponin T-positive cells in the selected viable cell population can be measured to calculate the proportion of cardiac troponin T-positive cells among all viable cells. For example, a viable cell population can be selected by gating from data obtained by flow cytometry analysis of a cardiomyocyte population, and the proportion of cardiac troponin T-positive cells in the viable cell population can be obtained based on the expression level of cardiac troponin T. For example, live cells in a cardiomyocyte group can be selected by forward scattering, side scattering, or staining with a dye for determining viability (nucleic acid-binding dye, protein-binding dye, etc.).
[0029] <(2) Spontaneous Beating Rate of 0 to 60 Beats / Minute> The spontaneous beating rate of the cardiomyocyte group of this embodiment is 0 to 60 beats / minute, preferably 0 to 50 beats / minute, more preferably 0 to 45 beats / minute, even more preferably 0 to 40 beats / minute, and particularly preferably 0 to 35 beats / minute. The spontaneous beating rate of the cardiomyocyte group may be 10 to 60 beats / minute, 10 to 50 beats / minute, 10 to 45 beats / minute, 10 to 40 beats / minute, or 10 to 35 beats / minute. The spontaneous beating rate of the cardiomyocyte group may be 20 to 60 beats / minute, 20 to 50 beats / minute, 20 to 45 beats / minute, 20 to 40 beats / minute, or 20 to 35 beats / minute.
[0030] The spontaneous beating rate (number of spontaneous beatings per unit time) of a cardiomyocyte group can be measured by a known method. The spontaneous beating rate of a cardiomyocyte group can be measured by any method capable of analyzing cell movement. Examples of measurement methods include acquiring images of a cardiomyocyte group, such as a video taken under a microscope, and analyzing them using a motion vector, or recording a potential pattern (spontaneous action potential) that changes with cell beating. Specific examples include a method using a patch clamp amplifier to measure the action potential duration (APD90) and spontaneous action potentials at 90% repolarization of a cardiomyocyte group, and a method using a multi-electrode system, calcium imaging, or impedance. The spontaneous beating rate is preferably measured using a number of cells appropriate for the method. However, multiple measurements can also be performed and the results statistically processed to obtain a value. Specifically, a method using a patch clamp amplifier to record the action potential duration (APD90) and spontaneous action potentials at 90% repolarization of a cardiomyocyte group can be used. The composition of the intracellular solution for measuring action potentials was potassium gluconate (130 mmol / L), KCl (10 mmol / L), NaCl (5 mmol / L), MgCl 2(1 mmol / L), glycol ether diamine tetraacetic acid (EGTA: 0.1 mmol / L), magnesium-bound adenosine triphosphate (0.1 mmol / L), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES: 10 mmol / L). The composition of the extracellular solution was NaCl (136.5 mmol / L), KCl (5.4 mmol / L), CaCl 2 (1.8 mmol / L), MgCl 2 (0.53 mmol / L), HEPES (85.5 mmol / L), and glucose (5.5 mmol / L).
[0031] <(3) Within 30 days from the initiation of differentiation> "Initiation of differentiation" refers to the time point at which human pluripotent stem cells are initiated in culture in a medium for inducing differentiation into cardiomyocytes (a medium containing a substance that induces differentiation into cardiomyocytes). "Within 30 days from the initiation of differentiation" refers to within 30 days from the time point at which human pluripotent stem cells are initiated in culture in a medium for inducing differentiation into cardiomyocytes. As described below, the cardiomyocyte population of this embodiment can be produced by (A) a step of inducing differentiation from pluripotent stem cells into cardiomyocytes, and (B) a step of removing pluripotent stem cells and non-cardiomyocytes. The cardiomyocyte population of this embodiment is one in which the step (B) is completed within 30 days from the initiation of the step (A). Conventionally, cells cultured for approximately 30 days from the initiation of differentiation induction from human pluripotent stem cells into cardiomyocytes correspond to human cardiomyocytes in the fetal to neonatal stage, and are smaller in size and less mature than mature human cardiomyocytes. On the other hand, it is known that continued culture for a long period of time, for example, for more than 40 days after the start of differentiation induction, increases the maturity of cardiomyocytes (Dhahri W. et al., (2022) Circulation, 145, 1412-1426.). However, long-term culture is costly and unsuitable for practical use. Long-term culture has problems such as a tendency for non-cardiomyocytes to increase or a decrease in cell adhesion, making it unsuitable for clinical application. The cardiomyocyte population of this embodiment has the characteristics (1) and (2) above and contains highly purified mature ventricular myocytes, even if the culture period is within 30 days after the start of culture for differentiation induction into cardiomyocytes. Therefore, it is a cardiomyocyte population suitable for clinical application. As in the method for producing cardiomyocyte populations described below, a method for producing highly purified cardiomyocytes that has a certain degree of maturity by limiting the number of culture days from the start of differentiation into cardiomyocytes to the completion of purification to within 30 days is a very advantageous method for clinical application.
[0032] When the cardiomyocyte population of this embodiment is produced by the steps (A) and (B) and then cryopreserved, the cryopreservation period is excluded from the period "within 30 days from the start of differentiation." In other words, the period from the start of the freezing treatment of the cardiomyocyte population to the completion of the thawing treatment of the frozen cardiomyocyte population is excluded from the period "within 30 days from the start of differentiation."
[0033] <Other Features> The above-described feature (2) of the cardiomyocyte cell population of this embodiment represents the maturity of the cardiomyocytes, and a "spontaneous pulsation rate of 0 to 60 beats per minute" indicates that the cardiomyocyte cell population contains a high proportion of ventricular myocytes. Furthermore, because the presence of pacemaker cells and / or atrial myocytes in the cardiomyocyte cell population increases the pulsation rate, the feature (2) also indicates a low content of these cells. Instead of or in addition to feature (2), the cardiomyocyte cell population of this embodiment can also be identified by, for example, a high content of myosin light chain 2v (MLC2v)-positive cells, a ventricular myocyte marker, in the cardiomyocyte cell population. The proportion of MLC2v-positive cells is preferably 70% or more, more preferably 80% or more, and particularly preferably 90% or more, at the time the cardiomyocyte cell population of this embodiment is transplanted into recipient myocardial tissue.
[0034] When used clinically, cardiomyocyte groups are usually cryopreserved and then thawed before use. A known cryopreservation solution for cells can be used to cryopreserve cardiomyocyte groups. Various cryopreservation solutions for cells are commercially available. One example is STEM-CELLBANKER (registered trademark) GMP grade (manufactured by Zenogen Pharma). Cryopreservation can be performed by suspending cardiomyocyte groups in a cryopreservation solution for cells and freezing the cell suspension.
[0035] The cardiomyocyte population of this embodiment may be responsive to antiarrhythmic drugs, such as adrenergic receptor agonists (e.g., isoproterenol), HCN channel blockers (e.g., ivabradine), and potassium channel blockers (e.g., amiodarone).
[0036] The cardiomyocyte cell population of this embodiment possesses all of the above characteristics (1) to (3), enabling clinical application as cardiomyocytes for transplantation. Because the cardiomyocyte cell population of this embodiment possesses characteristics (1) to (3), it is a cardiomyocyte cell population containing highly purified cardiomyocytes, particularly mature ventricular myocytes. As shown in the Examples described below, it is possible to electrically integrate with the recipient's cardiomyocytes and allow them to mature and survive for a long time, thereby regenerating damaged parts of the recipient's heart. Furthermore, as shown in the Examples described below, the cardiomyocyte cell population of this embodiment can provide a cell population for transplantation that exhibits a low incidence of long-lasting, severe ventricular arrhythmias in the recipient. Furthermore, because the cardiomyocyte cell population of this embodiment is differentiated from human pluripotent stem cells and highly purified, it can be safely transplanted into humans. Furthermore, as described below, it can be produced easily and industrially with advantageous results. Therefore, the cardiomyocyte cell population of this embodiment is highly useful as cardiomyocytes for transplantation.
[0037] (Cardiomyocyte spheroids) The cardiomyocyte group of this embodiment can also be used for cell transplantation as spheroidized cardiomyocyte spheroids (sometimes simply referred to as "cardiomyocyte spheroids" in this specification). The "spheroidized cardiomyocyte spheroids" of the second aspect of the present disclosure are cell masses formed by aggregation of cells contained in the cardiomyocyte group, and can be formed by the method described below.
[0038] The diameter of the cardiomyospheric spheres is not particularly limited as long as cells near the center of the cardiomyospheric spheres do not undergo cell death or cardiomyocytes near the center do not undergo significant blastogenesis compared to cardiomyocytes in other regions, but may be 50 μm or more and 300 μm or less. A more preferred range for the diameter of the cardiomyospheric spheres is 100 μm or more and 250 μm or less, and an even more preferred range is 150 μm or more and 200 μm or less. While spherical cardiomyospheric spheres are preferred, they may be any shape as long as they are cell aggregates and maintain the viability of cardiomyocytes in the cell aggregates. Therefore, the "diameter of the cardiomyospheric sphere" refers to the length from one end to the other of the cell aggregate passing through the center point. For example, if the cell aggregate is elliptical, the shortest length (minimum diameter) from one end to the other should be within the lower limit of the above range, and the longest length (maximum diameter) should be within the upper limit of the above range. Furthermore, in the case of a group of cardiomyospheric spheres containing a plurality of cardiomyospheric spheres, the above-mentioned preferred range of the diameter of the cardiomyospheric spheres does not mean that cardiomyospheric spheres of other sizes are not permitted to be included, and it is sufficient that 60% or more, preferably 70% or more, and further preferably 80% or more of the total number of cardiomyospheric spheres in the group of cardiomyospheric spheres have diameters within the above-mentioned range.
[0039] The diameter and distribution of cardiomyospheric diameters can be measured by known methods. Examples of measurement methods include measuring the diameter of cardiomyospheric diameters from images of cardiomyospheric diameters using image analysis software, and measuring the diameter using a particle size distribution analyzer. The cardiomyospheric diameters of this embodiment are aggregates of cardiomyocytes according to the first aspect described above. However, they do not necessarily have to be composed solely of cells. For example, they may be aggregates of cells around microcarriers (e.g., extracellular matrix particles) suitable for biotransplantation. Furthermore, the cardiomyospheric diameters of this embodiment serve as the active ingredient of the pharmaceutical composition described below. In this case, the ratio of cells constituting cardiomyospheric diameters to the total cells contained in the pharmaceutical composition is preferably 60% or more, more preferably 70% or more, and even more preferably 80% or more. The number of cells contained in cardiomyospheric diameters can be measured by any method capable of measuring this number. Examples of measurement methods include a method in which the relationship between the diameter of cardiomyospheric diameters and the number of cells contained in the cardiomyospheric diameters is previously obtained, and the number of cells contained in the pharmaceutical composition to be measured is then calculated from the diameter of the cardiomyospheric diameters and the number of cardiomyospheric diameters. The relationship between the diameter of a cardiomyospheric membrane and the number of cells contained in the cardiomyospheric membrane can be obtained, for example, by measuring the diameter of a plurality of cardiomyospheric membranes, disassembling the cardiomyospheric membranes into free cardiomyocytes, and counting the number of cardiomyocytes. The diameter of the cardiomyospheric membranes used to measure the number of cells in the cardiomyospheric membranes can be, for example, the maximum diameter of the cardiomyospheric membrane.
[0040] The cardiomyosphers of this embodiment may be produced from the cardiomyospheric cells according to the first aspect, and the cardiomyospheric cells themselves do not need to be produced within 30 days from the start of differentiation. It is sufficient that the production of the cardiomyospheric cells according to the first aspect for producing cardiomyospheric cells is completed within 30 days from the start of differentiation.
[0041] The inventors have found that when cardiomyocytes of the present embodiment are formed, the viability of the cardiomyocytes constituting the cardiomyocytes is maintained at a high level. Therefore, by forming cardiomyocyte groups into cardiomyocytes and recovering the cardiomyocytes, cardiomyocyte groups with a high ratio of viable cells can be obtained. Cardiomyocytes (cardiomyocyte groups) produced from the cardiomyocyte groups according to the first aspect contain highly purified mature cardiomyocytes and a high ratio of viable cells. Therefore, when transplanted into a recipient, the cardiomyocytes easily engraft into the recipient's myocardial tissue and have a low incidence of severe ventricular arrhythmias lasting for a certain period of time. Therefore, the cardiomyocytes are suitable for clinical applications.
[0042] (Pharmaceutical Composition) A third aspect of the present disclosure is a pharmaceutical composition comprising at least one selected from the group consisting of the cardiomyocyte population according to the first aspect and the cardiomyocyte spheres according to the second aspect, and a pharmaceutically acceptable carrier. The pharmaceutical composition of this embodiment contains, as an active ingredient, at least one selected from the group consisting of the cardiomyocyte population and cardiomyocyte spheres formed by spheroidizing the cardiomyocyte population. The pharmaceutical composition of this embodiment preferably has a viable cell ratio of 60% or more, more preferably 70% or more, of the total cells contained in the pharmaceutical composition. When stored or transported as a pharmaceutical composition, the viable cell ratio is preferably maintained throughout the storage and / or transport period, and more preferably until immediately before administration to the recipient. The viable cell count can be measured using known methods. For example, live and dead cells can be distinguished by trypan blue staining, the number of live cells and the number of dead cells can be counted, and the viable cell ratio can be calculated from the ratio of the number of live cells to the total number of cells.
[0043] Furthermore, the cardiomyospheric cells contained in the pharmaceutical composition of this embodiment preferably account for 60% or more, more preferably 70% or more, and even more preferably 80% or more of the total cells contained in the pharmaceutical composition. When the pharmaceutical composition is stored and / or transported, the ratio of cells constituting the cardiomyospheric cells is preferably maintained throughout the storage and / or transport period, and more preferably until immediately before administration to a recipient.
[0044] <Cardiomyocyte group and cardiomyospheric cells> The cardiomyocyte group and cardiomyospheric cells are the cardiomyocyte group according to the first aspect and the cardiomyospheric cells according to the second aspect.
[0045] Pharmaceutically acceptable carrier: A "pharmaceutically acceptable carrier" refers to a carrier that does not inhibit the physiological activity of an active ingredient and is not substantially toxic to a recipient. "Not substantially toxic" means that the ingredient is not toxic to a recipient at a commonly used dose. In the pharmaceutical composition of this embodiment, the pharmaceutically acceptable carrier is a carrier that does not damage the cardiomyocyte group according to the first aspect and is not substantially toxic to a recipient. Pharmaceutically acceptable carriers include any known pharmaceutically acceptable ingredient that is typically considered an inactive ingredient. Pharmaceutically acceptable carriers include, but are not limited to, solvents, diluents, vehicles, excipients, glidants, binders, granulating agents, dispersing agents, suspending agents, wetting agents, lubricants, disintegrants, solubilizers, stabilizers, emulsifiers, fillers, etc. Pharmaceutically acceptable carriers may be used alone or in combination.
[0046] The pharmaceutically acceptable carrier may be a buffer solution, such as saline, including common buffers (e.g., phosphate, citrate, and other organic acids).
[0047] The pharmaceutical composition may contain other ingredients in addition to the above-mentioned ingredients. The other ingredients are not particularly limited, and those commonly used in the pharmaceutical field can be used without particular limitation. Examples of the other ingredients include pharmaceutical additives other than those mentioned above. Examples of pharmaceutical additives include, but are not limited to, preservatives (e.g., antioxidants), chelating agents, flavoring agents, sweeteners, thickeners, buffers, colorants, etc.
[0048] The dosage form of the pharmaceutical composition is not particularly limited and can be any dosage form commonly used for pharmaceutical preparations. The pharmaceutical composition of this embodiment is typically a parenteral formulation and can be in a dosage form suitable for the specific administration method described below, such as an injection or a myocardial sheet. The pharmaceutical composition of this embodiment can optionally be cryopreserved for storage and transportation. If the pharmaceutical composition of this embodiment is frozen, the cells can be thawed and further diluted with a sterile carrier corresponding to the target cell type before use. The pharmaceutical composition of this embodiment is packaged, for example, in a vial for administration to a patient, but can also be packaged, for example, in a syringe depending on the administration method. After administration of the pharmaceutical composition of this embodiment, a commonly used immunosuppressant may be administered to the patient. The immunosuppressant can be selected appropriately for the patient, and examples include drugs that act on immunophilins (cyclosporine, tacrolimus hydrate, etc.). The pharmaceutical composition of this embodiment may also be used in combination with these immunosuppressants.
[0049] The administration route of the pharmaceutical composition of this embodiment is usually preferably parenteral administration. The administration route for parenteral administration may be any known method for administering cells to a patient, for example. Any method may be used as long as it is a minimally invasive method for administering cells to the patient's heart. Specifically, preferred local administration to the heart (particularly the ventricle or myocardial tissue) is administration from the epicardial side to ventricular myocardial tissue using a transplant needle or the like, or administration from the endocardial side or pericardial cavity using a catheter or the like.
[0050] The pharmaceutical composition can be administered in a therapeutically effective amount of the cardiomyocyte population according to the first aspect and / or the cardiomyocyte spheres according to the second aspect. "Therapeutically effective amount" means the amount of a drug effective for treating or preventing a target disease. For example, the therapeutically effective amount of the cardiomyocyte population and / or cardiomyocyte spheres can be an amount effective for cardiac repair in a recipient. The therapeutically effective amount may be determined appropriately depending on the patient's symptoms, weight, age, sex, etc., as well as the dosage form and administration method of the pharmaceutical composition. For example, the pharmaceutical composition can be administered in a single dose of the cardiomyocyte population and / or cardiomyocyte spheres, in an amount equivalent to 10 5 ~10 10pcs, preferably 10 7 ~10 9 There are several examples.
[0051] The pharmaceutical composition may be administered once or multiple times. For example, after administering the pharmaceutical composition to a patient, the patient's cardiac function, engraftment of transplanted cardiomyocytes, etc. may be monitored, and the pharmaceutical composition may be administered again as needed.
[0052] The pharmaceutical composition of this embodiment is administered to humans. The pharmaceutical composition can be used to treat cardiac diseases such as heart failure. Heart failure is a disease characterized by impaired cardiac function. Causes of heart failure include, for example, myocardial infarction, angina pectoris, hypertension, valvular disease, cardiomyopathy, arrhythmia, and congenital disease. The heart failure to be treated may be caused by any of these factors. The pharmaceutical composition of this embodiment can be suitably applied to the treatment of heart failure caused by damage to myocardial tissue due to the above-mentioned causes. By administering the pharmaceutical composition of this embodiment (transplantation of cardiomyocytes and / or cardiomyospheric cells) to a subject suffering from heart failure, the damaged myocardial tissue can be regenerated and cardiac function can be improved. Specifically, the pharmaceutical composition of this embodiment has the following functions: (1) the transplanted contractile cardiomyocytes can be engrafted into the damaged myocardium, directly enhancing the contractile force of the damaged site of the recipient heart, and / or (2) the release of paracrine factors that have angiogenic, cardioprotective, anti-inflammatory, anti-fibrotic effects, etc.
[0053] (Method for producing a cardiomyocyte population) A fourth aspect of the present invention is a method for producing a cardiomyocyte population. The method for producing a cardiomyocyte population of this aspect comprises the following steps (a) to (c) in this order: (a) a step of expanding human pluripotent stem cells, (b) a step of culturing the expanded human pluripotent stem cells under conditions that allow the human pluripotent stem cells to differentiate into cardiomyocytes, and producing a cell population containing cardiomyocytes at a ratio sufficient to ensure that cTnT-positive cells account for 90% or more, specifically 60% or more, after step (c), and (c) a step of removing the human pluripotent stem cells and non-cardiomyocytes from the cell population.
[0054] <Step (a)> Human pluripotent stem cells can be expanded by known methods, such as those described in Thomson et al., Science (1998) 282(5391):1145-7, Hovatta et al., EE, Ludwig et al., Nat Methods (2006) 3:637-46, Kennedy et al., Blood (2007) 109:2679-87, et al., Nat Methods (2011) 8:424-9, Wang et al., Stem Cell Res. (2013) 11(3):1103-16, and WO 2018 / 181342.
[0055] The medium may be prepared using a medium commonly used for culturing mammalian cells as the basal medium. Examples of basal media include BME medium, BGJb medium, CMRL 1066 medium, Glasgow MEM medium, Improved MEM Zinc Option medium, IMDM medium, Medium 199 medium, Eagle MEM medium, αMEM medium, DMEM medium, F-12 medium, DMEM / F12 medium, IMDM / F12 medium, Ham's medium, RPMI 1640 medium, and Fischer's medium, as well as mixtures thereof. Alternatively, commercially available basal media for stem cell culture may be used. Commercially available basal media include StemFit AS103C medium (Ajinomoto Co., Inc.), StemFit (registered trademark) AK medium (e.g., StemFit AK03N, StemFit AK02N) (Ajinomoto Co., Inc.), Essential 8 medium (Life Technologies, Inc.), mTeSR1 medium (STEMCELL Technologies, Inc.), TeSR2 medium (STEMCELL Technologies, Inc.), RHB medium (StemCells, Inc.), TeSR™-E6 (STEMCELL Technologies, Inc.), hESF-GRO medium (Nipro Corporation), HESF-DIF medium (Nipro Corporation), CSTI-7 (Cell Science Institute ... 6 medium (Life Technologies), etc.
[0056] From the viewpoint of avoiding contamination with chemically undefined components, the medium is preferably a chemically defined medium (CDM), and more preferably a serum-free medium. "Serum-free medium" refers to a medium that does not contain unconditioned serum or unpurified serum. Media containing purified blood-derived components and / or purified animal tissue-derived components (e.g., growth factors such as bFGF) are also included in the serum-free medium.
[0057] The serum-free medium may contain a serum substitute. Examples of serum substitutes include serum albumin, transferrin, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol, and 3'-thiolglycerol. Commercially available serum substitutes may be used. Examples of commercially available serum substitutes include Knockout TM Examples of such surfactants include, but are not limited to, Serum Replacement (Life Technologies), Chemically-defined Lipid Concentrated (Life Technologies), Glutamax™ (Life Technologies), B27 (Life Technologies), and N2 (Life Technologies).
[0058] In addition to L-tryptophan, the medium may contain some or all of the essential amino acids other than L-tryptophan (L-leucine, L-lysine, L-phenylalanine, L-isoleucine, L-threonine, L-histidine, L-methionine, and L-valine).
[0059] The medium may contain some or all of the non-essential amino acids (L-alanine, L-arginine, L-asparagine, L-aspartic acid, glycine, L-glutamine, L-glutamic acid, L-cysteine, L-serine, L-tyrosine, L-proline).
[0060] The medium may contain natural amino acids such as L-cystine in addition to the 20 amino acids mentioned above.
[0061] The medium may further contain medium additives. Examples of medium additives include, but are not limited to, ROCK (Rho-associated coiled-coil forming kinase / Rho-binding kinase) inhibitors such as Y-27632, antibiotics such as penicillin-streptomycin, vitamins, L-ascorbic acid, L-ascorbyl magnesium phosphate, sodium pyruvate, 2-aminoethanol, glucose, sodium bicarbonate, HEPES, insulin, progesterone, sodium selenate, and putrescine. The additives are preferably contained within a concentration range known per se.
[0062] The medium may contain fatty acids, including, but not limited to, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, palmitic acid, stearic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, butyric acid, acetic acid, palmitoleic acid, valeric acid, caproic acid, enanthic acid (heptylic acid), caprylic acid, pelargonic acid, capric acid, lauric acid, myristic acid, pentadecylic acid, margaric acid, hexenic acid, eleostearic acid, arachidic acid, 8,11-eicosadienoic acid, 5,8,11-eicosatrienoic acid, behenic acid, lignoceric acid, nervonic acid, cerotic acid, montanic acid, and melissic acid. The fatty acids may be saturated or unsaturated.
[0063] The medium may be a basal medium containing L-ascorbic acid, selenium, transferrin, insulin, FGF2 and TGFβ1, to which L-tryptophan or an L-tryptophan derivative has been added.
[0064] The pH of the medium is preferably about 6.0 to about 8.5, more preferably about 7.0 to about 7.5. The medium is preferably sterilized by filtration sterilization using a membrane filter or the like.
[0065] Human pluripotent stem cells can be cultured by known methods. For example, human pluripotent stem cells may be cultured using feeder cells such as fibroblasts, or may be cultured in a feeder-cell-free environment.
[0066] The culture vessel used for cell culture is not particularly limited as long as it is capable of culturing cells, and examples thereof include flasks, tissue culture flasks, dishes, Petri dishes, tissue culture dishes, multi-dishes, microplates, microwell plates, multi-plates, multi-well plates, microslides, chamber slides, petri dishes, tubes, trays, culture bags, and roller bottles.
[0067] Culture vessels used for cell culture may be cell-adhesive or cell-non-adhesive. Cell-adhesive culture vessels may be coated with any cell support substrate, such as Matrigel (Niwa A, et al. PLoS One. 6(7):e22261, 2011), fibrous proteins such as gelatin, collagen, and elastin; glycosaminoglycans such as hyaluronic acid and chondroitin sulfate; proteoglycans; fibronectin; vitronectin; and laminin, or artificial substances that mimic their functions, in order to improve cell adhesion to the surface of the culture vessel. Adherent culture is preferably performed using a culture vessel coated with the above-described cell support substrate.
[0068] The culture temperature is about 30 to 40°C, preferably about 37°C. 2 The concentration is about 1 to 10%, preferably about 2 to 5%. The oxygen concentration is usually 1 to 40%, but is appropriately selected depending on the culture conditions, etc.
[0069] <Step (b)> The method for inducing differentiation of human pluripotent stem cells into cardiomyocytes may be any method that can obtain the cardiomyocyte population of this embodiment. Examples of differentiation induction methods include (i) activating Wnt / catenin signaling in human pluripotent stem cells to obtain a first cell population (culture in a first differentiation medium), and (ii) inhibiting Wnt / β-catenin signaling in the first cell population to obtain a second cell population containing cardiomyocyte progenitor cells (culture in a second differentiation medium). Generally, after the Wnt / β-catenin signaling inhibition is terminated, the cardiomyocyte progenitor cells can be cultured for an additional 1 to 5 days in a medium such as RPMI medium, DMEM medium, or StemPro-34 to obtain a cardiomyocyte population containing mature ventricular myocytes. These steps can yield a cell population in which 60% or more of the total cells (excluding dead cells) in the medium have differentiated into cardiomyocytes.
[0070] Activation of the Wnt / catenin signal is achieved by contacting human pluripotent stem cells with a Wnt signal agonist, activin A, BMP4, bFGF, or the like. For example, the Wnt signal agonist may be an inhibitor of glycogen synthase kinase-3β (GSK-3β). The GSK-3β inhibitor may be at least one selected from the group consisting of low molecular weight chemical compounds, such as CHIR-99021, TWS119, SB216763, SB415286, and CHIR-98014. These compounds and their concentrations can be selected as concentrations at which cardiomyocytes having the characteristics of the cardiomyocyte group of this embodiment can be cultured. The expanded human pluripotent stem cells are cultured for 1 to 6 days in the first differentiation medium. Whether or not mesodermal cells have been obtained may be monitored. In this case, monitoring can be performed by the expression of mesodermal marker genes, specifically, for example, T, MIXL1, NODAL, etc. Next, the first differentiation medium is replaced with a second differentiation medium. The second differentiation medium contains a Wnt signaling antagonist, VEGF, etc. The Wnt signaling antagonist may be any one that generates the cardiomyocyte population of this embodiment, and examples include IWP-2, IWP-3, IWP-4, IWR-1, PNU-74654, XAV939, KY02111, etc. The type and concentration of these agents can be selected so that cardiomyocytes having the characteristics of the cardiomyocyte population of this embodiment are cultured. The cells are cultured in the second differentiation medium for 1 to 7 days. The culture period for steps (i) and (ii) is adjusted to within 30 days, including a subsequent 1-5 day culture period in a medium such as RPMI medium, DMEM medium, or StemPro-34 to obtain a cardiomyocyte population containing mature ventricular myocytes, and the culture period for step (c) described below. The culture vessels, culture conditions, etc. used in this step can be the same as those described in the expansion culture step of human pluripotent stem cells. Specifically, the differentiation induction into cardiomyocyte populations in this embodiment is preferably performed by the method described in Tohiyama S. et al., Stem Cell Reports. 2017;9:1406-1414.As the culture vessel, a four-layer culture plate commercially available from Thermo Tifer Scientific or the like is preferably used, and as the culture medium, StemFit AS301 medium or StemFit AS501 medium (manufactured by Ajinomoto Co., Inc.) is preferably used.
[0071] The proportion of cardiomyocytes in the cell population obtained by this step may be sufficient to ensure that the proportion of cTnT-positive cells is 90% or higher after step (c). Specifically, when purifying cells by culturing for approximately 4 days in step (c) described below, it is preferable that the proportion of cardiomyocytes is 60% or higher at the end of step (b). If the purification of cardiomyocytes is carried out over a longer period in step (c), the proportion may be lower. The proportion of cardiomyocytes can be calculated, for example, by measuring the proportion of cells positive for a cardiomyocyte marker such as cardiac troponin T by flow cytometry analysis.
[0072] <Step (c)> Human pluripotent stem cells and non-cardiomyocytes can be removed from the cell population after step (b) by known methods. For example, methods described in International Publication No. 2018 / 074457, Tanosaki S. et al., iScience. 2020;23:101535, Tanosaki S. et al., STAR Protoc. 2022;3:101360, Tohyama S. et al., Cell Metab. 2016;23:663-74, and Tohyama S. et al., Cell Stem Cell. 2013;12:127-37, etc., can be used. Specifically, a method can be used in which the cell population obtained in step (b) is cultured in a medium containing at least one inhibitor selected from the group consisting of a fatty acid synthesis inhibitor, a fatty acid utilization inhibitor, and a cholesterol synthesis inhibitor, thereby inducing cell death of the remaining undifferentiated cells and non-cardiomyocytes.
[0073] Fatty acid synthesis inhibitors that inhibit fatty acid synthesis by targeting at least one factor selected from the group consisting of ATP citrate lyase, fatty acid synthase, acetyl-CoA carboxylase, and malonyl-CoA decarboxylase are preferred, and those that inhibit fatty acid synthesis by targeting at least one factor selected from the group consisting of ATP citrate lyase and fatty acid synthase are preferred. Fatty acid synthesis inhibitors that inhibit fatty acid synthesis by targeting fatty acid synthase include orlistat, C75, flavonoids, epigallocatechin-3-gallate (EGCG), etc., with orlistat and C75 being preferred, and orlistat being more preferred. Fatty acid synthesis inhibitors that inhibit fatty acid synthesis by targeting ATP citrate lyase include LY294002 and SB204990. Examples of fatty acid synthesis inhibitors that inhibit fatty acid synthesis by targeting acetyl-CoA carboxylase include soraphen A, TOFA, A769662, metformin, and AICAR, with TOFA and A769662 being preferred.
[0074] The fatty acid utilization inhibitor is preferably one that inhibits fatty acid utilization by targeting carnitine palmitoyltransferase 1. Examples of fatty acid degradation inhibitors that target carnitine palmitoyltransferase 1 and inhibit fatty acid degradation include etomoxir, perhexiline, ranolazine, etc., with etomoxir and perhexiline being preferred.
[0075] The cholesterol synthesis inhibitor is preferably one that inhibits cholesterol synthesis by targeting at least one factor selected from the group consisting of acetyl-CoA acetyltransferase, HMG-CoA synthase, and HMG-CoA reductase, and more preferably one that inhibits cholesterol synthesis by targeting HMG-CoA reductase. Examples of cholesterol synthesis inhibitors that target HMG-CoA reductase and inhibit cholesterol synthesis include pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, cerivastatin, lovastatin, and mevastatin, with pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin being preferred, and simvastatin being more preferred.
[0076] Among these, it is preferable to use one or more selected from the group consisting of orlistat, C75, LY294002, SB204990, etomoxir, perhexiline, simvastatin, and salts thereof, and it is more preferable to use orlistat.
[0077] The concentrations of the fatty acid synthesis inhibitor, fatty acid utilization inhibitor, and cholesterol synthesis inhibitor in the medium can be appropriately selected depending on their types. For example, the concentration of the fatty acid synthesis inhibitor or fatty acid utilization inhibitor can be 0.1 to 500 μM. The concentration of the cholesterol synthesis inhibitor can be 0.01 to 50 μM.
[0078] For example, the medium used in this step can be prepared by adding at least one selected from the group consisting of a fatty acid synthesis inhibitor, a fatty acid utilization inhibitor, and a cholesterol synthesis inhibitor to the above-mentioned basal medium. The medium may also contain at least one compound selected from the group consisting of glucose, glutamine, and methionine. The inclusion of glucose, glutamine, and / or methionine is expected to improve cell growth.
[0079] The cell culture in step (c) can be carried out under conditions generally used for cell culture. The culture temperature can be about 30 to 40°C, preferably about 37°C. 2 The concentration is about 1 to 10%, preferably about 2 to 5%. The oxygen concentration is usually 1 to 40%, but is appropriately selected depending on the culture conditions, etc.
[0080] The culture time is not particularly limited, but is preferably 24 hours or more, more preferably 48 hours or more, and specifically 1 to 5 days. If necessary, the cells may be subcultured.
[0081] Human pluripotent stem cells and non-cardiomyocytes can be removed from the cell population obtained in step (b) by culturing the cell population in a medium containing at least one inhibitor selected from the group consisting of a fatty acid synthesis inhibitor, a fatty acid utilization inhibitor, and a cholesterol synthesis inhibitor. Furthermore, in addition to the above steps, the cells can be further cultured in a medium typically used for cell culture that does not contain glucose, glutamine, or glutamic acid, but does contain lactic acid, thereby selectively proliferating cardiomyocytes and inducing cell death in non-cardiomyocytes. Culturing in such a medium can further highly purify cardiomyocytes. This method is specifically described in International Publication Nos. 2007 / 088874 and 2016 / 010165. In addition, in the cardiomyocyte group of the first aspect, the characteristic "(3) within 30 days from the start of differentiation" means that the date of starting culture in a medium for inducing cardiomyocyte differentiation (a medium containing a substance that induces differentiation into cardiomyocytes; for example, the first differentiation medium) in the above step (b) is the starting date, and the date of completion of step (c) is within 30 days.
[0082] <Optional Steps> (Selection Step) The production method of this embodiment may include, after the steps (a) to (c), a step (selection step) of selecting a cardiomyocyte population having the characteristics (1), (2), and (3) above. The selection step can be performed by the method described in the section (Cardiomyocyte Population) above. Specifically, for example, it can be performed as follows. From the cell population obtained in step (c), a cell population that has been differentiated within 30 days since the start of step (b) is selected (d1). Next, a cardiomyocyte population in which cardiac troponin T-positive cells account for 90% or more of all viable cells is selected. For example, using an antibody against cardiac troponin T, flow cytometry analysis is performed on the cell population obtained in step (c), and a cell population in which the ratio of troponin T-positive cells to all viable cells is 90% or more is selected (d2). Next, from the cell population selected above, a cardiomyocyte population with a spontaneous beating rate of 0 to 60 beats per minute is selected. For example, the action potential duration at 90% repolarization (APD90) and spontaneous action potentials of a group of cardiomyocytes are recorded using a patch clamp amplifier, and a group of cells with a spontaneous beating rate of 0 to 60 beats / min is selected (d3). In this manner, the selection step can be performed. The order of steps (d1) to (d3) is not limited to the above-mentioned order, and the order may be changed as desired.
[0083] (Step of Freezing Cardiomyocyte Groups) The manufacturing method of this embodiment may include a step of freezing cardiomyocyte groups after the above steps (a) to (c), and optionally after the selection step. The cardiomyocyte groups obtained by the above method are preferably detached from the culture plate by a method known per se, washed as necessary, and then suspended in a cell cryopreservation solution typically used for cryopreserving cells, after removing the final medium. An example of a cell cryopreservation solution is STEM-CELLBANKER (registered trademark) GMP grade (manufactured by Zenogen Pharma). The concentration of cardiomyocyte groups in the cell suspension to be cryopreserved may be any concentration that does not cause cell death due to freeze-thawing, specifically, any concentration that results in a viable cell rate after freeze-thawing of 50% or more of the viable cells before freezing. Specifically, the concentration of cardiomyocyte groups in the cell suspension may be, for example, 1 x 10 5 pieces ~ 1×10 8 / mL, preferably 1 x 106 pieces ~ 1×10 7 The cell concentration is 1 / mL. Freezing containers can be vials, bags, or the like used for freezing cells. Freezing and cryopreservation can be performed using known methods. For example, a method can be used in which cardiomyocyte groups are frozen in a freezer at -60°C to -80°C, then transferred to a container filled with liquid nitrogen or a deep freezer at -150°C or below for long-term storage. Cell freezing while controlling the temperature using a programmable freezer is also preferred. For example, a method can be used in which the cells are cooled to -40°C to 60°C at a rate of 1 to 10°C / min, left at -40°C to -60°C for 10 to 1 hour, then cooled to -80°C at a rate of 1 to 10°C / min, and then cooled at -80°C for several days. Thawing of frozen cardiomyocytes can be performed using known methods. For example, the frozen cells can be removed from the liquid nitrogen storage container or deep freezer and thawed in a 37°C water bath.
[0084] (Method for producing cardiomyocytes) A fifth aspect of the present disclosure is a method for producing cardiomyocytes. The method of the fifth aspect includes a step of statically culturing the cardiomyocytes according to the first aspect in a state where the cardiomyocytes are suspended in a culture solution in an incubator having microwells on the bottom surface. The cardiomyocytes according to the second aspect can be produced by the production method according to the fifth aspect.
[0085] Cardiomyospheric spheres can be formed by suspending the cardiomyocytes according to the first embodiment in a medium and statically culturing them in a culture vessel having microwells on the bottom. The cardiomyocytes according to the first embodiment used here do not form spheroids. Cardiomyocytes according to the first embodiment can be produced by the production method according to the fourth embodiment.
[0086] Examples of the medium include the basal medium described above. It is preferable to use a serum-free medium. The medium may contain insulin (0.1 to 10 mg / L), transferrin (0.1 to 10 μg / L), selenium (0.1 to 10 μg / L), basic fibroblast growth factor (bFGF; 1 ng / ml to 100 ng / ml), epidermal growth factor (1 ng / ml to 1000 ng / ml), platelet-derived growth factor (1 ng / ml to 1000 ng / ml), and endothelin-1 (ET-1) (1×10 -8 ~1 x 10 -6 It is preferable that the medium contains at least one selected from the group consisting of StemFit AS301 medium (manufactured by Ajinomoto Co., Inc.).
[0087] As a culture vessel having a microwell on the bottom surface, commercially available culture vessels for spheroid formation can be used. Microwells are, for example, wells with an opening diameter on the order of micrometers (e.g., 100 to 1000 μm, preferably 100 to 800 μm, more preferably 200 to 500 μm, and even more preferably 300 to 500 μm). Preferably, the culture vessel has a low-adhesion culture surface. Culture vessels coated with a biomaterial adhesion inhibitor such as Prevelex (registered trademark) (manufactured by Nissan Chemical Industries, Ltd.) may be used. A specific example of a culture vessel is a Prevelex-coated 6-well plate (Elplasia RB 500 400 NA 6, manufactured by Corning).
[0088] The production of cardiac spheres may be performed with reference to methods described in known literature (e.g., International Publication No. 2009 / 017524, Kawaguchi S. et al., JACC Basic Transl Sci. 2021; 6: 239-254, Tabei R. et al., The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation. 2019; 38: 203-214).
[0089] (Method for treating heart failure) A sixth aspect of the present disclosure is a method for treating heart failure, comprising administering at least one selected from the group consisting of the cardiomyocytes according to the first aspect and the cardiomyocyte spheres according to the second aspect to a subject in need of treatment for heart failure.
[0090] The administered cardiomyocytes and / or cardiospheres may be in the form of a pharmaceutical composition according to the third aspect.
[0091] Cardiomyocyte groups and / or cardiomyospheroids can be administered to a subject, for example, by direct injection into myocardial tissue. Any instrument can be used for administration as long as it can inject cardiomyocyte groups and / or cardiomyospheroids into the transplant target tissue, and for example, those described in International Publication No. 2020-013125 can be used. A 24- to 30-gauge injection needle is used. A catheter or the like can also be used.
[0092] A "therapeutically effective amount" of cardiomyocytes and / or cardiomyosphers can be administered to a patient in need of treatment for heart failure. The therapeutically effective amount may be determined appropriately depending on, for example, the degree of damage to the myocardial tissue in the patient. For example, a single dose of cardiomyocytes and / or cardiomyosphers may be administered in the amount of 10 cardiomyocytes. 5 ~10 10 10 were mentioned. 7 ~10 9 Here, when cardiomyospheric cells are administered, the amount of cells to be administered is counted as the number of cells in the cardiomyocyte group that has become cardiomyospheric cells.
[0093] The therapeutic method of this embodiment is applicable to humans. Heart failure is a disease characterized by impaired cardiac function. Causes of heart failure include, for example, myocardial infarction, angina pectoris, hypertension, valvular disease, cardiomyopathy, arrhythmia, and congenital disease. The heart failure to be treated may be caused by any of these factors. The pharmaceutical composition of this embodiment can be suitably applied to the treatment of heart failure caused by damage to myocardial tissue due to the above-mentioned causes. By administering the pharmaceutical composition of this embodiment (transplantation of cardiomyocytes and / or cardiomyospheric cells) to a subject suffering from heart failure, the damaged myocardial tissue can be regenerated and cardiac function can be improved. Specifically, the pharmaceutical composition of this embodiment has the following functions: (1) the transplanted contractile cardiomyocytes can be engrafted into the damaged myocardium, directly enhancing the contractile force of the damaged site of the recipient heart; and / or (2) the release of paracrine factors that have angiogenic, cardioprotective, anti-inflammatory, anti-fibrotic effects, etc.
[0094] <Other Aspects> Another aspect of the present disclosure is the use of at least one selected from the group consisting of the cardiomyocytes according to the first aspect and the cardiomyosphers according to the second aspect in the manufacture of a pharmaceutical composition for the treatment of heart failure. Another aspect of the present disclosure is at least one selected from the group consisting of the cardiomyocytes according to the first aspect and the cardiomyosphers according to the second aspect for use in the treatment of heart failure. Another aspect of the present disclosure is the use of at least one selected from the group consisting of the cardiomyocytes according to the first aspect and the cardiomyosphers according to the second aspect in the treatment of heart failure.
[0095] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.
[0096] Example 1: Production and analysis of human iPS cell-derived cardiomyocyte populations (1) Preparation of purified human iPSC-derived cardiomyocyte populations Human iPS cells (FfI14s04 line) (provided by the Foundation for iPS Cell Research, Kyoto University) were maintained on iMatrix511 (Nippi Corporation)-coated culture plates using StemFit AS103C media (Ajinomoto Co., Inc.). Differentiation into cardiomyocytes was induced on a four-layer culture plate (Thermo Fisher Scientific) using StemFit AS301 medium (Ajinomoto Co., Inc.) according to the method described in Tohyama S. et al., Stem Cell Reports. 2017;9:1406-1414. After differentiation induction, the remaining human iPS cells in the cell population obtained after differentiation induction were removed using the fatty acid synthesis inhibitor orlistat according to the method described in Tanosaki S. et al., iScience. 2020;23:101535, and Tanosaki S. et al., STAR Protoc. 2022;3:101360. Next, cardiomyocytes were purified using StemFit AS501 (Ajinomoto Co., Inc.) according to the method described in Tohyama S. et al., Cell Metab. 2016;23:663-74., and Tohyama S. et al., Cell Stem Cell. 2013;12:127-37. The purified cardiomyocyte population was cryopreserved using STEM-CELLBANKER (registered trademark) GMP grade (Zenogen Pharma). The culture for differentiation induction was carried out for 7 to 15 days, and the culture for removal of remaining human iPS cells was carried out for 5 to 10 days.
[0097] (2) Flow cytometry and electrophysiological analysis of the resulting human iPS cell-derived cardiomyocyte population. The human iPS cell-derived cardiomyocyte population prepared and frozen in (1) was thawed according to the method described in Tohyama S. et al., Cell Metab. 2016;23:663-74 and Tohyama S. et al., Cell Stem Cell. 2013;12:127-37, and the cardiomyocyte population was analyzed. The results are shown in Figures 1A to 1F. Figure 1A(b) shows the results of flow cytometry analysis of the cardiac troponin T positivity rate of the thawed cardiomyocyte population. Dead cells were excluded by gating, and the cardiac troponin T positivity rate among live cells was calculated. The cardiac troponin T (cTnT) positivity rate of the cardiomyocyte population prepared in (1) after thawing was 99.8% (Figure 1A(b)). The cardiac troponin T (cTnT) positivity rate of the cell group before the above purification was 81.0% (FIG. 1A(a)).
[0098] In addition, the thawed cardiomyocyte population was electrophysiologically analyzed using the patch clamp method according to the method described in Ichimura H. et al., Sci Rep. 2020;10:11883. Specifically, the human iPS cell-derived cardiomyocyte population cryopreserved in (1) was thawed, and the thawed cardiomyocyte population was cultured for 4 days. To examine the spontaneous beating rate, the action potential duration at 90% repolarization (APD90) and spontaneous action potentials were recorded using a patch clamp amplifier (Axopatch 200B, Molecular Devices). Action potentials were recorded in an intracellular solution (potassium gluconate (130 mmol / L), KCl (10 mmol / L), NaCl (5 mmol / L), MgCl 2 (1 mmol / L), glycol ether diamine tetraacetic acid (EGTA: 0.1 mmol / L), magnesium-bound adenosine triphosphate (0.1 mmol / L), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES: 10 mmol / L)), and extracellular solution (NaCl (136.5 mmol / L), KCl (5.4 mmol / L), CaCl 2 (1.8 mmol / L), MgCl 2(0.53 mmol / L), HEPES (85.5 mmol / L), glucose (5.5 mmol / L)).
[0099] The results of 65 analyses (for 65 cells) are shown in Figures 1B and 1C. As shown in Figure 1B, cells contained in the human iPS cell-derived cardiomyocyte group prepared in (1) exhibited a ventricular-like action potential pattern after freeze-thawing. Furthermore, as shown in the left panel of Figure 1C (Beat rate), the spontaneous beat rate was 34 ± 13 beats / min. As shown in the middle panel of Figure 1C (MDP), the maximum diastolic potential (MDP) was -58.4 ± 0.64 mV. As shown in the right panel of Figure 1C (APD90), the action potential duration at 90% repolarization (APD90) was 465 ± 25 ms. Meanwhile, the spontaneous beat rate of a cell group (n = 7) that underwent only the cardiomyocyte differentiation step using the method in (1) above, without the purification step, was also analyzed (Figure 1G). As is clear from Figure 1G, the purified human iPS cell-derived cardiomyocyte group had an average spontaneous beat rate of approximately 38 beats per minute, while the unpurified cell group had a higher spontaneous beat rate of approximately 60 beats per minute.
[0100] (3) Drug responsiveness analysis of the obtained human iPS cell-derived cardiomyocyte population The human iPS cell-derived cardiomyocyte population prepared and cryopreserved in (1) was thawed and cultured for approximately one week in MEMα (Thermo Fisher, cat. 4061029) containing 2.5% FBS (MERC) and sodium pyruvate (MERCK, cat. S8636). After completion of the culture, using a culture vessel coated with Pluronic (registered trademark) F-127 (AAT Bioquest, cat. 20053), probenecid (AAT Bioquest, cat. 20062) and 5 mM Cal520AA (AAT Bioquest, cat. 21131) The cells were cultured at 37 ° C. for 1 hour in HBSS (Thermo Fisher, cat. 14025092).
[0101] After culturing, the adrenergic receptor agonist isoproterenol (MERCK, cat. I6504) was added to the medium containing the cell population at 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, or 1 μM, respectively, and calcium transients were measured using FDSS / μCELL (Hamamatsu Photonics). Furthermore, the HCN channel blocker ivabradine (MERCK, cat. SML02c81) was added to the medium containing the cell population at 10 nM, 30 nM, 100 nM, 300 nM, or 1 μM, respectively, and calcium transients were similarly measured. Furthermore, amiodarone (MERCK, cat A8423), a potassium channel blocker, was added to the medium containing the cultured cell population at concentrations of 0.1 μM, 0.3 μM, 1 μM, 3 μM, or 10 μM, and calcium transients were measured in the same manner.
[0102] The results are shown in Figures 1D and 1E. Analysis was performed on three different cell populations prepared by the method described in (1). As is clear from Figures 1D and 1E, the human iPS cell-derived cardiomyocyte populations obtained in (1) responded concentration-dependently to isoproterenol, an adrenergic receptor agonist, ivabradine, an HCN channel blocker, and amiodarone, a potassium channel blocker.
[0103] (4) Immunocytochemical Analysis of the Obtained Human iPS Cell-Derived Cardiomyocytes The human iPS cell-derived cardiomyocytes prepared and frozen in (1) were thawed according to the method described in Tohyama S. et al., Cell Metab. 2016;23:663-74 and Tohyama S. et al., Cell Stem Cell. 2013;12:127-37. The thawed cardiomyocytes were immunostained using anti-actinin, anti-vimentin, and anti-DAPI antibodies according to standard methods. The results are shown in Figure 1F(a). Most of the cells contained in the human iPS cell-derived cardiomyocytes prepared in (1) were actinin-positive and vimentin-negative. The results of immunostaining the same cells using anti-MLC2v, anti-MLC2a, and anti-DAPI antibodies are shown in Figure 1F(b) and 1F(e). Of the human iPS cell-derived cardiomyocytes generated in (1), 85% were mature ventricular myocytes positive for MLC2v alone, whereas 7% were immature cardiomyocytes positive for MLC2a alone or cells positive for both MLC2v and MLC2a (Fig. 1F(b), 1F(e)). Furthermore, analysis of the expression of connexin 43 and N-cadherin in a similar manner revealed abundant expression of both (Fig. 1F(c) and 1F(d)). Collectively, these findings indicate that the human iPS cell-derived cardiomyocytes generated in (1) are composed of almost pure ventricular myocytes with a maturity similar to that of adult cardiomyocytes.
[0104] (Example 2: Production and analysis of cardiomyocytes) (1) Production of cardiomyocytes from human iPS cell-derived cardiomyocytes The human iPS cell-derived cardiomyocytes cryopreserved in Example 1 (1) were suspended in StemFit AS301 medium and seeded onto a 6-well plate (Elplasia RB 500 400 NA 6, Corning) coated with Prevelex (registered trademark) (Nissan Chemical Industries, Ltd.) in the same manner as described in Kawaguchi S. et al., JACC Basic Transl Sci. 2021;6:239-254 or Tabei R. et al., The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2019;38:203-214, and cultured for 2 days. After culturing for a total of 7 days while replacing half of the medium every two days, human iPS cell-derived cardiomyocyte spheres (hiPSC-CSs) were collected.
[0105] The size of the cardiomyospheric spheres contained in the obtained cardiomyospheric spheres was measured using a particle size distribution analyzer (Beckman Coulter). As a result, the average diameter of the cardiomyospheric spheres contained in the cardiomyospheric spheres was approximately 150 μm. Furthermore, a portion of the cardiomyospheric spheres was treated in a 3:1 solution of trypsin / EDTA and Accumax at 37°C for 10-15 minutes immediately after harvesting from the culture plate and 4 hours after harvesting from the culture plate to disaggregate the cardiomyospheric spheres into single cells, which were then stained with trypan blue. The viability of cells contained in individual cardiomyospheric spheres as determined by this analysis is shown in Figure 2A. In Figure 2A, "253G4" indicates the results of cardiomyospheric spheres prepared by the method described in this Example from cardiomyocytes differentiated, purified, and frozen from the research human iPS cell line 253G4 (provided by Kyoto University) using the method described in Example 1(1). As can be seen from Figure 2A, trypan blue staining of the cardiomyospheric cells immediately after collection (0 h) and 4 hours later (4 h) determined that both the 253G4 and Ffl14s04 strains were derived from 90% or more of the cells, with the Ffl14s04 strain derived cells being determined to be 95.8 ± 2.2% (N = 3). Furthermore, the number of cardiomyospheric cells with a diameter of 50 μm or more in a given field of view of the solution containing the collected cardiomyospheric cells was counted to calculate the number of cardiomyocytes constituting the cardiomyospheric cells (number of cardiomyospheric cells). The number of cardiomyospheric cells and single cells with a diameter of 50 μm or less in the same field of view was counted to calculate the number of these cells. The ratio of cardiomyospheric cells to the total number of cells was calculated using the following formula, which was 74-86%. Percentage of cardiomyospheric cells (%) = (number of cardiomyospheric cells) / [(number of cardiomyospheric cells) + (number of non-cardiomyospheric cells)] × 100
[0106] (2) Long-term culture of human iPS cell-derived cardiomyocyte spheres. The cardiomyocyte spheres obtained in (1) above were further cultured for a long period in the same medium. After 28, 56, or 84 days of culture, the cardiomyocytes were cultured for 1 hour using CytoRed solution (molecular weight = 313.31, Fujifilm Wako Pure Chemical Industries, Ltd.). These cardiomyocytes were embedded in OCT compound (Tissue-Tek OCT Compound, Sakura Corporation) and then cryosectioned to a thickness of 10 μm using a cryostat (CM3050S, Leica Microsystems). The sections were immunohistochemically analyzed using anti-DAPI antibody, a primary antibody against human-specific cardiac troponin I (cTnI, ab52862; Abcam), and a biotin-conjugated secondary antibody (Vector Laboratories). The results are shown in Figure 2C. As shown in Figure 2C (A, D, and G), CytoRed solution and other substances were observed to permeate through the center of the cardiomyocytes from the external culture medium, indicating that the cardiomyocytes in the cardiomyocytes could receive nutrients directly from the external culture medium. Furthermore, as shown in Figure 2C (B, E, and H), the cardiomyocytes maintained their purity even after 12 weeks of culture.
[0107] (3) Transplantation of human iPS cell-derived cardiomyocyte spheres into adult male NOG mice. Adult male NOG mice (In Vivo Science) were anesthetized with a low dose of isoflurane and artificially ventilated using a rodent ventilator. A left thoracic incision was made in the fourth intercostal space, and modified luciferase (Akaluc)-expressing human iPS cell-derived cardiomyocytes or modified luciferase (Akaluc)-expressing human iPS cell-derived cardiomyocytes (1 × 10 6The transplanted mice were anesthetized 7, 14, and 28 days after transplantation, and Akalumine n-Hydrochloride (Fujifilm Corporation, 20 nmol / g body weight) was administered intraperitoneally. 10 minutes after administration, images were taken using an imaging system (NEWTON 7.0 FT500, Vilber) with a 20 cm x 20 cm aperture and 1 minute exposure time, and the images were analyzed using Quant software. The results are shown in Figures 2D and 2E. As can be seen from Figures 2D and 2E, cardiomyospheric spheres were more effectively transplanted into the animal's heart than cardiomyocytes.
[0108] (Example 3: Cardiomyospheric Spheroid Transplantation into Cynomolgus Monkeys) (1) Induction of Cardiac Ischemia-Reperfusion Injury in Cynomolgus Monkeys In accordance with Japanese domestic regulations and guidelines, all experimental procedures were reviewed by the Animal Care and Use Committee and ultimately approved by the President of Shinshu University (No. 300023), Keio University (No. A2022-180), and Ina Research (No. 18088). Two weeks before cardiomyospheric spheroid transplantation, myocardial infarction was induced in a total of 10 cynomolgus monkeys (also known as macaca fascicularis), four males and six females, using the following method. Surgery was performed as described in Ichimura H. et al., Sci Rep. 2020;10:11883 or Kobayashi H. et al., Methods Mol Biol. 2021;2320:295-3023. Specifically, cynomolgus monkeys were anesthetized with an intramuscular injection of ketamine and xylazine, intubated with a tracheal tube (3.5 mm diameter), and mechanically ventilated with 2% isoflurane. Buprenorphine was administered subcutaneously on a regular basis to alleviate postoperative pain. Blood pressure, oxygen saturation, and electrocardiogram (ECG) were monitored throughout the procedure. Phenylephrine was administered intravenously to maintain adequate blood pressure. After a median sternotomy, a 4-0 silk suture was passed through the myocardium at the center of the left anterior descending (LAD) coronary artery and threaded through a polyethylene tube. A silicone tube was placed over the polyethylene tube and tied off with the suture. Before induction of ischemia, 1 mg / kg lidocaine and 200 U / kg heparin were administered intravenously. Subsequently, the same amount of heparin was administered every hour until reperfusion. After 180 minutes of mid-LAD occlusion, the tube was removed and the heart was allowed to reperfuse.
[0109] (2) Preparation and transportation of cardiomyospheric spheres for transplantation The cardiomyospheric spheres produced in Example 2(1) were collected on the day of transplantation, diluted with physiological saline, packaged in Eppendorf tubes, and transported to a transplantation facility at 4° C. Immediately after arrival at the transplantation facility, they were transplanted into cynomolgus monkeys by the method described below.
[0110] (3) Transplantation of Cardiomyocytes Four male and six female cynomolgus monkeys in which myocardial infarction was induced as described above were divided into two groups with equal male-female ratios. One group received the cardiomyocytes (2 × 10 7In one group, cardiac spheres (equivalent to 6 x 10 cardiomyocytes) were transplanted, and in the other group, a vehicle was transplanted by the following method. Twelve weeks after transplantation, the monkeys were euthanized and histological analysis was performed. Cardiac function and arrhythmia were monitored during the observation period. Furthermore, 10 cynomolgus monkeys (4 males, 6 females) in which myocardial infarction was similarly induced were divided into two groups, and one group received the cardiomyocytes (6 x 10 cardiomyocytes) described above in (2). 7 One group was transplanted with 1000 mice (equivalent to 1000 mice), and the other group was transplanted with the vehicle.
[0111] The specific transplantation method was as follows. On day 14 after myocardial infarction (MI) induction, a second sternotomy was performed on the animals to expose the heart. The cardiac spheres (2) above suspended in saline or saline vehicle were injected 5 to 6 times at 100 μL each using a 27-gauge syringe needle and administered intramyocardially to the infarcted area and border area. Immunosuppression was achieved by intravenous injection of methylprednisolone and abatacept (Bristol Myers Squibb) and subcutaneous injection of cyclosporine (Novartis International AG). Methylprednisolone (Bristol Myers Squibb) was administered at a daily dose of 50 mg / kg for 3 days starting 1 day before transplantation. Thereafter, 2 mg / kg of methylprednisolone (Bristol Myers Squibb) was administered once daily. Abatacept (Bristol Myers Squibb) was administered at a dose of 12.5 mg / kg every two weeks starting one day before transplantation. The daily dose of cyclosporine (Novartis International AG) was 5-10 mg / kg, and the dose was adjusted based on peripheral blood trough levels from day 5 after transplantation until the end of the experiment. Cyclosporine trough levels are shown in Figure 2F (cardiomyocytes 2 x 10 7 100 cells) and Figure 2G (6 x 10 cardiomyocytes were transplanted) 7 (Equivalent to 10 cardiomyocytes were transplanted)
[0112] (4) Means and Methods for Analyzing Animals After Cardiosphere Transplantation (Confirmation of Myocardial Infarction Model) The onset of myocardial infarction was confirmed by transient ST elevation on the electrocardiogram and an increase in serum cTnT levels.
[0113] Echocardiography was performed using a VIVID 7 system (GE Healthcare Biosciences) on days 0, 28, and 84 after transplantation. After intramuscular injection of ketamine and xylazine, the heart was observed in a short-axis view from the parasternal space. Left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) were measured in M-mode, and the left ventricular shunt fraction (FS) was calculated using the following formula: FS (%) = 100 × [(LVEDD - LVESD) / LVEDD]
[0114] (Computed Tomography) Computed tomography (CT) was performed 2 days before transplantation, 28 days after transplantation, and 84 days after transplantation. The CT scans were performed using the method described in Shiba Y. et al., Nature. 2016;538:388-391. Specifically, anesthetized animals were intubated and mechanically ventilated with 2% isoflurane. Images of the heart were captured using an R_mCT AX (Rigaku Corporation) while a radiocontrast agent (Iopamidol) was infused at 8 ml / min. The systolic and ventilatory cycles were automatically synchronized. Left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) were measured using Ziostation2 software (Amin). Left ventricular ejection fraction (LVEF) was calculated using the following formula: LVEF (%) = 100 x [(LVEDV-LVESV) / LVESV]
[0115] Holter electrocardiogram recordings were performed 4 days before implantation and on days 4, 7, 14, 28, 42, 56, 70, and 83 after implantation. Two-lead electrodes were placed on the precardiac system and connected to a Holter recorder. Animals were required to wear a jacket to protect the ECG system, and 24-hour ECG recordings were performed. Ventricular tachycardia was defined as four or more consecutive premature ventricular complexes with a ventricular rate greater than 150 bpm. Sustained ventricular tachycardia was defined as ventricular tachycardia lasting for 30 seconds or longer. All analyses were performed by an operator blinded to the study groups.
[0116] (Blood Tests) Peripheral blood was collected, plasma was separated, and brain natriuretic peptide (BNP) levels were measured. Cardiac troponin T (cTnT) levels in peripheral blood were measured 12 days before transplantation (48 hours after induction of myocardial infarction) and 10 days before transplantation (96 hours after induction of myocardial infarction). Cyclosporine trough levels were measured using whole blood by electrochemiluminescence immunoassay.
[0117] (Histological Examination) On day 84 after transplantation, animals receiving cardiosphere transplants were euthanized and subjected to complete necropsy. Hearts were harvested, cut into 5-mm-thick cross sections, and fixed in 4% paraformaldehyde. All sections were routinely stained with hematoxylin and eosin (HE) and picrosirius red (PSR) to determine scar area. Scar area was calculated by subtracting the graft area from the total fibrous area (shown in red by PSR staining) if the graft was located within the scar. Sections were analyzed immunohistochemically using a primary antibody against human-specific cardiac troponin I (cTnI, ab52862; Abcam) and a biotin-conjugated secondary antibody (Vector Laboratories). For color detection, an HRP-labeled streptavidin ABC kit (Vector Laboratories) was used, followed by a DAB substrate kit (Vector Laboratories).
[0118] The sections were stained with the following antibodies: anti-myosin light chain 2A primary antibody (MLC-2A; S58-205, Becton, Dickinson and Company), anti-myosin light chain 2V primary antibody (MLC-2V; ab92721, Abcam), anti-α-actinin primary antibody (ab137346, Abcam), anti-vimentin primary antibody (Merck & Co.), anti-connexin 43 primary antibody (Cx43, ab11370, Abcam), anti-N-caderin primary antibody (Thermo Fisher Scientific), as described above. Immunohistological analysis was performed using primary antibodies against cTnT (clone: 13-11, manufactured by Scientific), primary antibodies against CD45 (clone: 2B11&PD), primary antibodies against Ki67 (ab16667, manufactured by Abcam), primary antibodies against pan-cadherin (clone: CH-19), primary antibodies against lycopersic lectin (tomato lectin, Dilight 594-labeled tomato lectin; manufactured by Vector Laboratories), and species-specific fluorescence (Thermo Fisher Scientific).
[0119] The brain, lung, liver, kidney, and spleen were also collected and fixed in 4% PFA. Unless macroscopic abnormalities were detected, several randomly selected sections were immunostained using antibodies against HE and human-specific cTnI to detect ectopic cardiomyocyte engraftment. Stained sections were imaged using a NanoZoomer 2.0-RS (Hamamatsu Photonics) or a BZ-X700 microscope (KEYENCE).
[0120] Statistical Analysis: Echocardiograms, computed tomography (CT), BNP levels, graft area, and outcomes were analyzed by analysis of variance (ANOVA), followed by post-hoc comparisons between time points with Tukey's multiple comparison test, and unpaired t-test analysis for group comparisons at each time point. cTnT rates were analyzed by ANOVA followed by post-hoc Tukey's multiple comparison test. All summarized data are presented as mean ± standard error of the mean. All statistical analyses were performed using GraphPad Prism (GraphPad Software), with a significance threshold of P<0.05.
[0121] (5) Analysis Results of Animals After Cardiomyospheric Spheroid Transplantation (Histological Examination) In Example 3(3), human iPS cell-derived cardiomyospheroids (2 × 10 7 Hearts harvested from animals receiving 6 × 10 cardiomyocytes (equivalent to 6 × 10 cardiomyocytes) on day 84 (12 weeks) after transplantation were stained with picrosirius red. Results showed no significant difference between vehicle- and cardiomyocyte-transplanted animals (9.12 ± 1.74% vs. 5.24 ± 0.49% of the total left ventricular area, p = 0.15). 7 Animals transplanted with cardiomyocyte-equivalent cardiomyocytes and 2 × 10 7 There was no difference in scar area between the two groups when compared with animals transplanted with cardiomyocyte-equivalent cardiomyocytes (Fig. 4B(a)). 7 Compared with animals transplanted with cardiomyocyte-equivalent cardiomyocytes, 6 × 10 7 In animals receiving cardiomyocyte-equivalent cardiospheres, the transplant area increased 13-fold (Figures 4B(b) and 4B(c)). These grafts were substantial, accounting for 11.0±1.6% of the scar area. Furthermore, the transplanted cardiomyocytes were identified using a human-specific cardiac troponin I antibody, and the hearts of four of the five transplanted animals showed essentially no signs of graft rejection. Furthermore, the cardiomyocytes of the transplanted animals displayed a streaky pattern similar to that of host cardiomyocytes, with comparable cTnT expression and sarcomere length (Figure 2B), demonstrating that by 12 weeks post-transplantation, they had matured within the myocardial tissue of the transplanted animals at approximately the same level as host cardiomyocytes.
[0122] In Example 3(3), human iPS cell-derived cardiomyospheric spheres (6 × 10 7No signs of ectopic cardiomyocyte transplantation were observed in the lungs, liver, kidneys, or spleen, other than the heart, of animals that received transplants of ectopic cardiomyocytes (equivalent to individual cardiomyocytes) (Figures 6A-I). All transplanted cells were cTnT-positive cardiomyocytes. Most cardiomyocytes were of the MLC2v-positive mature ventricular subtype, but only a few expressed MLC2a (Figure 4A(F)). Ki67-positive cells were also present in the transplanted area, but most were cTnT-negative non-cardiac cells, and only a few Ki67-positive cardiomyocytes were present 12 weeks after transplantation (Figure 4A(G)). The transplanted cardiomyocytes were well vascularized (Figures 4A(J), 4A(M)) and abundantly expressed connexin43 and cadherin (Figures 4A(H), (I), (K), (L)). These results indicate that the transplanted cardiomyocytes survive at a maturity similar to that of the host cardiomyocytes.
[0123] (Echocardiography) In Example 3(3), human iPS cell-derived cardiomyospheric spheres (2 × 10 7 The left ventricular shunt fraction (FS) was measured by echocardiography before transplantation, 4 weeks after transplantation, and 12 weeks after transplantation for animals that received 6 × 10 cardiomyocytes (equivalent to 1 × 10 cardiomyocytes) and the vehicle. The results are shown in Figure 3A. As can be seen from Figure 3A, the contractile function was significantly improved in animals that received cardiomyocyte transplantation 4 weeks after transplantation. 7Figure 5A shows echocardiograms of animals receiving cardiomyocyte-equivalent cardiomyocyte transplants before, 4 weeks after, and 12 weeks after transplantation, and Figure 5B shows LVEF measurements. Echocardiograms showed higher fractional shortening in cardiomyocyte-transplanted animals than in vehicle-transplanted animals, and this advantage persisted up to 12 weeks after transplantation. Meanwhile, a study was also conducted in which cardiomyocytes were prepared using human iPS cell-derived cardiomyocytes that had undergone only the cardiomyocyte differentiation step (see Example 1(1)) but not the purification step, and transplanted into cynomolgus monkeys using a method similar to Example 3(3). Left ventricular shunt fraction (FS) was measured by echocardiographic analysis before, 4 weeks after, and 12 weeks after transplantation for these non-purified cardiomyocyte-transplanted and vehicle-transplanted animals. The results are shown in Figure 5D, along with the results for animals receiving cardiomyocytes prepared from purified human iPS cell-derived cardiomyocytes. As is clear from Figure 5D, animals that received transplants of cardiomyospheric spheres produced from purified human iPS cell-derived cardiomyocytes (hiPSC-CSs (purified)) showed significantly improved contractile function 4 weeks after transplantation compared to animals that received transplants of cardiomyospheric spheres produced from unpurified human iPS cell-derived cardiomyocytes (hiPSC-CSs (non-purified)).
[0124] (CT Examination) In Example 3, human iPS cell-derived cardiomyospheric spheres (6 × 10 7 Computed tomography (CT) scans were performed on animals receiving transplants of cardiomyocytes (equivalent to individual cardiomyocytes) and vehicle-transplanted animals 2 days before transplantation, 28 days after transplantation, and 84 days after transplantation. The left ventricular ejection fraction (LVEF) calculated from the results is shown in Figure 5B(a). At 4 and 12 weeks after transplantation, the left ventricular ejection fraction of cardiomyocyte-transplanted animals was significantly higher than that of vehicle-transplanted animals.
[0125] (Blood test) In Example 3(3), human iPS cell-derived cardiomyocytes (2 × 10 7 Individual cardiomyocyte equivalent (Fig. 5E-A and B), 6 x 10 7In animals transplanted with human iPS cell-derived cardiomyocytes (Figures 5E-C and 5E-D) and vehicle-transplanted animals, peripheral blood samples were collected 2 and 4 days after transplantation, and cardiac troponin T (cTnT) levels were measured. Furthermore, peripheral blood samples were collected 14 days after transplantation, and serum brain natriuretic peptide (BNP) levels were measured. These results are shown in Figure 5E. As is clear from Figures 5E-A and 5E-C, both animals transplanted with human iPS cell-derived cardiomyocytes and vehicle-transplanted animals had elevated serum cTnT levels, confirming an ischemic state (Figures 5E-A and 5E-C). Furthermore, serum BNP levels were also confirmed to be comparable between vehicle-transplanted animals and animals transplanted with human iPS cell-derived cardiomyocytes.
[0126] (Holter ECG) In Example 3, Holter ECG was recorded from animals transplanted with human iPS cell-derived cardiomyospheric spheres and vehicle-transplanted animals before transplantation, on days 4, 7, and 14 after transplantation, and every other week thereafter. Vehicle recipients showed no substantial ventricular arrhythmias ( Figures 3C(a) and 3C(c) ). Four of the five animals transplanted with human iPS cell-derived cardiomyospheric spheres also showed no or minimal ventricular arrhythmias throughout the experimental period ( Figures 3C(b) and 3C(d) ). One of the transplanted animals (ID: C067 in Figure 5D ) showed transient ventricular tachycardia (lasting 9 minutes and 14 seconds in one day) up to two weeks after transplantation ( Figure 5D ), but no ventricular arrhythmias were observed thereafter ( Figures 3B , 3C(b), and 3C(d) ).
[0127] In Example 3, human iPS cell-derived cardiomyocytes (6 × 10 7 Similar analyses were performed on animals receiving transplants of cardiospheres (equivalent to individual cardiomyocytes) and vehicle-transplanted animals. The results are shown in Figure 5C. As can be seen from Figure 5C, two out of four animals receiving cardiosphere transplants (IDs: C096 and C100 in Figure 5) exhibited sustained ventricular arrhythmias, but no sustained ventricular arrhythmias were observed after day 14 (Figures 5C(b) and (d)). These ventricular arrhythmias, with a maximum rate of 176 bpm, lasted for only 11 minutes 6 seconds and 16 minutes 3 seconds, respectively (Figure 5D).
[0128] The transient ventricular arrhythmias that occurred in some of the animals transplanted with human iPS cell-derived cardiomyospheric spheres in Example 3 were significantly shorter in duration and less frequent than in previous studies (Shiba Y. et al., Nature. 2016;538:388-391). The short duration and low frequency of arrhythmias may be explained by differences in the transplanted human iPS cell-derived cardiomyocytes. Specifically, the differences in iPS cell-derived cardiomyocytes are thought to be a combination of factors such as the high purity and maturity of the cardiomyocytes in the cardiomyocyte population produced in Example 1, or the high proportion of viable cells in the cardiomyocyte population transplanted into cynomolgus monkeys in Example 3.
[0129] The present inventors have demonstrated a method for directly transplanting human pluripotent stem cell-derived cardiomyocytes (PSC-CMs) into the myocardium, as described in Example 3. While this method involves potential risks associated with needle injection, such as tissue damage, bleeding, thrombosis, and cardiac edema, the transplanted PSC-CMs have been shown to contract in synchronization with adjacent recipient cardiomyocytes, a process known as cardiac regeneration therapy. The cardiomyocytes prepared in Example 2 have several advantages and could be ideal active ingredients for cardiac regeneration therapy. First, cardiomyocytes are easily prepared; they are simply seeded onto a specific culture plate and allowed to naturally form cell aggregates. This simplicity is particularly important when preparing large numbers of cardiomyocytes, such as for human cardiac regeneration therapy. Second, because cardiomyocytes maintain viability for at least 24 hours at 4°C in normal saline, this pharmaceutical composition can be transported from the CPC to multiple medical institutions, eliminating the need for cell processing prior to transplantation. Finally, the cardiomyocytes prepared in Example 2 effectively engraft into recipient myocardial tissue without the use of additives. As described in Example 3, 6 × 10 7 Animals transplanted with cardiomyocyte-containing cardiomyocyte-containing cardiospheres exhibited substantial-sized CM grafts occupying 11.0±1.6% of the scar area, with significant contractile recovery even 12 weeks after transplantation.
[0130] The post-transplant arrhythmias observed in Example 3 showed similar characteristics to those in a previous study (Shiba Y, et al., Nature. 2016;538:388-391, cardiomyocyte purity 63%), i.e., delayed onset, non-lethal, and transient occurrence. However, the duration and frequency of arrhythmias in Example 3 were significantly shorter and lower than those observed in the previous study (Figure 5F). The lower incidence of post-transplant arrhythmias may be due to the different origin of the transplanted cardiomyocytes. Previous studies used allogeneic monkey-derived CM, whereas Example 3 used xenogeneic human-derived CM. However, other xenotransplantation studies (Liu YW, et al., Nat Biotechnol. 2018;36:597-605; Chong JJ, et al., Nature. 2014;510:273-7; Romagnuolo R, et al., Stem Cell Reports. 2019;12:967-981; Wahiba D. et al., Circulation. 2022;145;1412-1426 (US20200407687)) have documented a high incidence of sustained ventricular arrhythmias after transplantation.
[0131] In other xenotransplantation studies mentioned above, for example, Liu YW, et al., Nat Biotechnol. 2018;36:597-605., the purity of transplanted cardiomyocytes was 86-99%, but the frequency and duration of sustained ventricular arrhythmias were high. Also, Chong JJ, et al., Nature. 2014;510:273-7., the purity of transplanted cardiomyocytes was 73±12%, but the frequency and duration of sustained ventricular arrhythmias were high. Furthermore, Romagnuolo R, et al., Stem Cell Reports. 2019;12:967-981., the average purity of transplanted cardiomyocytes was 81.9%±3.9%, and the viable cell ratio was 80.7%±2.4%, but the frequency and duration of ventricular arrhythmias were high. In Wahiba D. et al., Circulation. 2022;145;1412-1426, the spontaneous beating rate of transplanted cardiomyocytes was 45 bpm on day 20 of culture and approximately 30 bpm on day 40 of culture, but ventricular arrhythmia was observed. From these points, it was shown for the first time that in order to achieve a low frequency and onset time of ventricular arrhythmia after transplantation in Example 3, it is necessary to satisfy at least two conditions: the purity of the cardiomyocytes in the cardiomyospheric spheres transplanted in Example 3 is 99.8% and the spontaneous beating rate is 34±13 beats / min. Furthermore, the human iPS cell-derived cardiomyocytes produced in Example 1 took a maximum of 25 days for the differentiation and purification processes, which differs from the production of cardiomyocytes matured by long-term culture.
[0132] In summary, when clinical-grade iPSC-CM preparations were transplanted into infarcted primate hearts, long-term graft survival and improved contractility were confirmed, although transient non-lethal arrhythmias occurred, which is considered to be manageable within acceptable limits. The human iPS cell-derived cardiomyocyte populations produced in Example 1 exhibited properties such as cardiac troponin T-positive cells at 90% or higher (Figure 1A(b)) and spontaneous beating rates of 0-60 beats per minute (Figure 1C). Furthermore, the cardiomyocyte spheres produced in Example 2 were produced using cardiomyocyte populations within 30 days (excluding the frozen storage period) from the start of differentiation in Example 1. Cardiomyocyte populations with these characteristics are thought to be able to electrically integrate with the recipient cardiomyocytes and maintain their maturity for long periods of time, thereby regenerating the damaged portion of the recipient heart (Figures 2B, 3A, 4A, 4B, 5A, 5B). Furthermore, among the transplanted animals, some did not exhibit ventricular arrhythmia, and the arrhythmias that did occur in some were significantly less frequent than in previous studies, were transient, and were manageable (Figs. 3C, 5C, and 5D). Based on these properties, the cardiomyocyte population prepared in Example 1 and the cardiomyospheric cells prepared in Example 2 can be used as cell preparations suitable for clinical applications.
[0133] According to the present invention, there are provided cardiomyocyte cell populations and cardiomyospheroids derived from human pluripotent stem cells that can meet the conditions necessary for clinical application, as well as pharmaceutical compositions containing the cardiomyocyte cell populations and / or cardiomyospheroids as active ingredients, methods for producing the cardiomyocyte cell populations, and methods for producing the cardiomyospheroids.
[0134] Although the preferred embodiments of the present invention have been described above, the present invention is not limited to these embodiments. Addition, omission, substitution, and other modifications of the configuration are possible within the scope of the spirit of the present invention. The present invention is not limited by the above description, but is limited only by the scope of the appended claims.
Claims
1. A group of cardiomyocytes comprising ventricular muscle cells differentiated from human pluripotent stem cells, the group of cardiomyocytes having the following characteristics (1), (2), and (3): (1) cardiac troponin T positive cells account for 90% or more of all live cells, (2) spontaneous pulsation is 0-60 beats per minute, and (3) differentiation has commenced within 30 days.
2. The cardiomyocyte group according to claim 1, having a spontaneous pulsation of 0 to 50 times per minute.
3. A pharmaceutical composition comprising at least one selected from the group consisting of the cardiomyocyte group according to claim 1 or 2 and cardiomyocyte spheroids formed by spheroidizing the cardiomyocyte group, and a pharma- ceutically acceptable carrier.
4. The pharmaceutical composition according to claim 3, wherein the ratio of live cells among all cells in the group of cardiomyocytes is 80% or more.
5. The pharmaceutical composition according to claim 3, wherein the ratio of cells constituting cardiomyocytes to the total cells contained in the pharmaceutical composition is 60% or more.
6. The pharmaceutical composition according to claim 3, for use in the treatment of heart failure.
7. A method for producing a group of cardiomyocytes described in claim 1 or 2, comprising the steps of: (a) expanding and culturing human pluripotent stem cells; (b) culturing the expanded human pluripotent stem cells under conditions for differentiating them into cardiomyocytes to produce a group of cells containing 60% or more cardiomyocytes; and (c) removing human pluripotent stem cells and non-cardiomyocytes from the group of cells.
8. A cardiomyocyte spheroid formed by spheroidizing the cardiomyocyte group according to claim 1 or 2.
9. The myocardial sphere according to claim 8, wherein the diameter of the myocardial sphere is 50-300 μm.
10. A method for producing cardiomyocyte spheres, comprising the steps of suspending a group of cardiomyocytes according to claim 1 or 2 in a medium and then statically culturing the cells in an incubator having microwells on the bottom surface.
Citation Information
Patent Citations
Multi-donor stem cell composition and method for producing the same
JP2023088954A
Mature Cardiomyocyte Compositions
US20200407687A1
Method for purifying cardiac myocyte and presumptive cardiac myocyte derived from stem cell and fetus
WO2007088874A1
Additive for undifferentiation maintaining medium
WO2018181342A1
Injection instrument set
WO2020013125A1
